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INVESTIGATION OF THE EFFECTS OF ENTEROBACTER GROUP OF 
MICROORGANISMS ON COLON CANCER 
SUMMARY 
Many studies have been performed to determine the interaction between some 
bacterial species and cancer. However, there has been no attempts to demonstrate a 
possible relationship between Enterobacter spp. and colon cancer. Therefore, it is 
aimed to investigate the effects of Enterobacter group of microorganisms on colon 
cancer in the present study. Determination of the interaction between Enterobacter 
spp. and colon cancer will lead to new approaches to colon cancer initiation and 
mechanism. Identification of a possible interaction between colon cancer and 
Enterobacter spp. may also be important for development of prophylaxis and new 
treatment strategies. 
 
Two strains of Enterobacter spp. and one strain of Escherichia coli were isolated 
using Sheep Blood Agar from patients who were treated at Istanbul University, 
Istanbul Faculty of Medicine, Department of General Surgery. Eight strains of 
Enterobacter spp. and one strain of Morganella morganii were provided from 
Marmara University, School of Medicine, Department of Medical Microbiology. 
One Enterobacter spp. strain that was isolated from environmental samples was 
obtained from Microbial Collection Unit at Yeditepe University, Genetics and 
Bioengineering Department. Then strains were identified based on FAME profiles, 
biochemical activities and 16S rDNA sequencing. Bacterial protein from thirteen 
strains was isolated, protein concentration was determined by Bradford Assay. The 
optimum protein concentration to apply onto NCM460 (Incell) and CRL1790 
(ATCC) cell lines was determined by MTS assay. Cell viability and proliferation was 
also determined. For statistical analysis Graphpad Software was used. The values 
were analysed using One way ANOVA test following Dunnett test. Before and after 
bacterial protein application, CD24 was detected by flow cytometry, apoptosis 
detection was performed using annexin V. Then, bacterial proteins were isolated 
from the strains which increase cell viability and proliferation and decrease the 
apoptosis was applied onto cell lines. RNA was isolated, cDNA was synthesized. 
NFKB and Bcl2 expression was determined by CFX96 Real Time PCR Detection 
System. Statistical analysis was performed by One way ANOVA following Tukey 
test in Graphpad Software. To detect COX-2 on those strains Western Blotting 
technique was used. Phylogenetic analysis was performed by SDSC Biology 
Workbench. 
 
xx 
 
Among thirteen bacterial strains tested in this study, six of them were defined as 
effective either on CRL1790 or NCM460 cell line. All effective strains increased the 
cell viability and proliferation at their optimum concentrations and decreased 
apoptosis. Also, they were determined as COX-2 negative. By molecular techniques 
based on 16S rDNA sequences, fatty acid compositions and metabolic activities, HIA 
and DE51 were identified as Escherichia coli and Morganella morganii, 
respectively. It was found that the remaining four effective strains belonged to the 
Enterobacter genus. Three of them signed as DB7Y, DE129 and DE365 decreased 
apoptosis by increasing NFKB and Bcl2 expression. Also DE365 increased CD24 
level in CRL1790. DE8, which was identified as Enterobacter aerogenes, increased 
CD24 level as well as NFKB expression on CRL1790. However, it did not affect 
Bcl2 expression. In addition to the increase in NFKB expression, these results 
indicate that DE8 may follow another pathway for apoptosis reduction. This 
suggestion was confirmed by drawing the phylogenetic tree of the effective 
Enterobacter strains. When the effective Enterobacter strains were examined in a 
phylogenetic tree, it was observed that DE8 was located far from the others. 
 
Apoptosis inhibition is an important pathogenicity mechanism which enables the 
bacteria to replicate inside host cells. Some bacteria induce apoptosis but in that case 
they target immune cells like macrophages and neutrophils because otherwise these 
cells will kill them. Apoptosis inhibition can be observed in many bacterial strains. 
Our study was the first to demonstrate apoptosis can be inhibited by Enterobacter 
strains. Apoptosis inhibition is so important for cancer development since apoptosis 
is a complex process that contains many pathways, at any point along these pathways 
defects can occur which lead to malignant transformation of the affected cells, tumor 
metastasis and resistance to anticancer drugs. In the previous studies, it was reported 
that the proto-oncogene Bcl-2, which inhibits apoptosis encourages tumor 
progression and reduction of apoptosis is important for carcinogenesis. 
 
In conclusion, the present study, the data indicated that Enterobacter strains might 
promote colon cancer. This is the first study showing that Enterobacter spp. may be 
a clinically important factor for colon cancer initiation and progression. Studies can 
be extended on animal models in order to develop new strategies for treatment. 
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ENTEROBACTER GRUBU MİKROORGANİZMALARIN KOLON KANSERİ 
ÜZERİNE ETKİLERİNİN ARAŞTIRILMASI 
ÖZET 
Kanser, hücrelerin kontrolsüz olarak çoğaldığı bir hastalıktır. Düzensiz, kontrolsüz 
çoğalma neticesinde tümör oluşumu görülür. Kolon kanseri, görülme sıklığı 
açısından dünyada üçüncü sıradadır. Kolon kanserinin oluşumunda genetik 
yatkınlığın yanısıra yaş, beslenme, fiziksel aktivite eksikliği, fazla kilolu veya obez 
olma gibi faktörler de etkilidir.  
 
Apoptoz hücre ölümünden sorumlu çok aşamalı bir mekanizmadır. Sadece gelişim 
esnasında değil yetişkin organizmalarda hücre sayısının kontrolü amacıyla 
kullanılmaktadır. Hücre büzülmesi, kromatin yoğunlaşması, çekirdek ve hücre 
parçalanması apoptozun en bilinen özellikleridir. Apoptoz ayrıca hastalık ya da 
zararlı ajanlar sonucu hücre hasar gördüğü zaman aktifleştirilen bir koruma 
mekanizmasıdır. Hücre büzülmesi ve piknoz apoptozun erken aşamalarında görülür. 
Hücre büzülmesi neticesinde hücre boyutu küçülür, sitoplazma  yoğunlaşır ve 
organeller daha sıkı paketlenirler. Kromatin yoğunlaşmasından sonra piknoz oluşur. 
Apoptotik yapılar fagositik hücreler tarafından yutulmaktadırlar. Çalışmalar apoptoz 
azalmasının veya apoptoza karşı gelişen direncin kanserleşmeyle ilgisi olduğunu 
göstermektedir.  
 
Kolon ve rektum kanserlerinin farklı çeşitleri bulunmaktadır. Bunlar arasında 
barsaktaki özel hormon üreten hücrelerde başlayan karsinoid tümörler olabileceği 
gibi, kolon duvarında yer alan Kajal hücrelerinde başlayan tümörler de yer alır. Bu 
tümörler selim yada habis olabilirler. Sindirim sisteminin herhangi bir bölgesinde 
görülebilirler fakat kolonda nadir olarak görülürler. Lenfomalar lenf düğümlerinde 
görülmekle beraber kolonda da başlayabilmektedirler. Sarkomalar nadir olarak kolon 
ve rektum duvarındaki kan damarları ve bağ dokusundan gelişirler. Kolorektal 
kanserlerin % 95 inden fazlası adenokarsinomadır.  
 
Kolorektal kanser kolon veya rektum epitelinde bulunur, ilk aşama polip 
oluşumudur. Daha sonra tümör hücreleri yayılır, epiteli geçerek kaslar, lenf 
düğümleri, karaciğer ve diğer organlara dağılır. Kalıtsal kolorektal kanser, bazı 
genlerde mutasyon oluşumuyla başlar. Bu hastalığın oluşumunda en önemli bir başka 
sebep ise inflamasyondur. Ülseratif kolit ve inflamatuvar barsak hastalığı geçirmiş 
hastalarda kolon kanseri olma riski yüksektir. Kolitin süresi ve anatomik genişliği 
riski arttırmaktadır. İnflamasyon, kolit ve kolon kanseri ile neticelenen hücre hasarı 
oluşturan, oksidatif stres oluşumuna yol açar. Inflamasyon sonucu makrofaj ve diğer 
lökositlerden tümör başlangıcına yol açabilecek mutasyonlara sebep olan reaktif 
oksijen ve nitrojen türleri üretilmektedir. Tümör hücrelerinin yayılmaları için gerekli 
olan taban zarının yıkımını lökositler ve diğer immün hücreleri gerçekleştirmektedir. 
xxii 
 
Nötrofiller, eozinofiller, dendritik hücreler, mast hücreleri ve lenfositler de epitel 
kaynaklı tümörlerin oluşumunda aktiflerdir.  
 
 
Bakteri türleri ve kanser arasındaki ilişkiyi tespit etmek üzere pek çok çalışma 
yapılmıştır. Fakat Enterobacter spp. ve kolon kanseri arasındaki muhtemel ilişkiyi 
gösterebilecek herhangi bir girişimde bulunulmamıştır. Bu nedenle, bu çalışmada, 
Enterobacter grubu mikroorganizmaların kolon kanseri üzerine etkilerinin 
araştırılması amaçlanmaktadır. Enterobacter spp. ve kolon kanseri arasındaki 
ilişkinin tespit edilmesi kolon kanseri başlangıcı ve mekanizmasına yönelik yeni 
yaklaşımlara yol açabilecektir. Ayrıca Enterobacter spp. ve kolon kanseri arasında 
olası bir ilişkinin tanımlanması profilaksi ve yeni tedavi geliştirmek için önem 
taşımaktadır. 
 
 
Çalışmamızda İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Genel Cerrahi Anabilim 
Dalı’nda tedavi gören hastalardan İki Enterobacter spp. ve bir Escherichia coli suşu 
Koyun Kanlı Agar kullanılarak izole edilmiştir. Sekiz Enterobacter spp. ve bir 
Morganella morganii suşu da Marmara Üniversitesi, Tıp Fakültesi, Tıbbi 
Mikrobiyoloji  Anabilim Dalı’ndan temin edilmiştir. Çevresel örneklerden izole 
edilmiş olan bir Enterobacter spp. suşu ise Yeditepe Üniversitesi, Genetik ve 
Biyomühendislik Bölümü’ndeki Mikrobiyal Koleksiyon Biriminden elde edilmiştir. 
Bu suşlar daha sonra, yağ asidi metil ester profilleri, sahip oldukları biyokimyasal 
aktiviteler ve 16S rDNA dizilemesi ile tanımlanmıştır. Onüç suştan bakteriyel protein 
izole edilmiş, protein konsantrasyonu Bradford testi ile belirlenmiştir. NCM460 
(Incell) ve CRL1790 (ATCC) hücre hatları üzerine uygulanacak en uygun protein 
konsantrasyonu MTS testi ile saptanmıştır. Hücre canlılığı ve çoğalması da ayrıca 
tespit edilmiştir. İstatistik analiz için Graphpad Software kullanılmıştır. Değerler 
‘One way ANOVA’ testini takiben Dunnett test ile analiz edilmiştir.  
 
CD24 prematüre lenfositler,  epitel ve sinir hücrelerinde üretilen bir yüzey 
proteinidir. CD24’ ün pek çok kanser dokusunda ve kolon kanserinde arttığı tespit 
edilmiştir. Çalışmamızda, bakteri proteini uygulama öncesi ve sonrasında, CD24 
flow sitometri ile saptanmıştır. Apoptoz tespiti annexin V kullanılarak yapılmıştır. 
Apoptotik hücrelerde hücre dışı ortama zar fosfolipid fosfatidilserin çıkışı olur. 
Annexin, Ca+
2
 varlığında negatif yüklü fosfolipidlere  yüksek afinite gösteren bir 
proteindir, fosfatidilserin’e bağlanır. Annexin V, FITC ile birleştirilmiştir, tespiti 
flow sitometi ile yapılmaktadır. Erken apoptotik, geç apoptotik, nekrotik veya canlı 
hücre ayrımını belirleyebilmek için pi kullanılmıştır.  
 
Çalışmamızda daha sonra hücre canlılığı ve çoğalmasını arttırarak, apoptozu düşüren 
suşlardan bakteriyel proteinler izole edilmiş, hücre hatlarına uygulanmıştır. RNA 
izole edilmiş, cDNA üretilmiş, NFKB ve Bcl2 ekspresyonu CFX96 Real Time PCR 
Detection System ile saptanmıştır. NFKB, proliferasyon , apoptoz ve kanserleşmede 
etkili olan bir proteindir. Bcl2 da pek çok kanser hücresinde artan bir apoptoz 
düzenleyicisidir. Real-time datalarının istatistiksel analizi Graphpad Software’deki 
‘One way ANOVA’ı  takiben Tukey test ile yapılmıştır. 
 
Cox-2, prostaglandin sentezinde etkili olan bir enzimdir. Bcl2 ekspresyonunu 
arttırarak apoptozu inhibe eder. Apoptozu düşürüp canlılığı arttıran altı suştan izole 
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edilen proteinler hücrelere uygulanmış, inkübasyon sonrası hücre lizatları elde 
edilmiş, Cox-2 saptanması için Western Blotting tekniği kullanılmıştır. Filogenetik 
analiz SDSC Biology Workbench ile yapılmıştır. 
 
Bu çalışmada test edilen onüç bakteri suşu arasından altısı CRL1790 veya NCM460 
hücre hattı üzerinde etkili olarak tanımlanmıştır. Bütün etkili suşlar, en uygun 
konsantrasyonlarda hücre canlılığı ve çoğalmasını arttırmış, apoptozu düşürmüştür. 
Ayrıca, örneklerin COX-2 negatif olduğu belirlenmiştir. 16S rDNA dizileri, yağ asidi 
kompozisyonu ve metabolik aktiviteye dayanan moleküler tekniklerle HIA ve DE51 
sırasıyla Escherichia coli ve Morganella morganii olarak tanımlanmıştır. Geriye 
kalan dört etkili suşun ise Enterobacter cinsine ait olduğu bulunmuştur. DB7Y, 
DE129 ve DE365 olarak kodlanan üç suşun NFKB ve Bcl2 ekspresyonunu arttırarak 
apoptozu düşürdüğü saptanmıştır. Ayrıca DE365 CRL1790’de CD24 seviyesini 
arttırmıştır. Enterobacter aerogenes olarak tanımlanan DE8, CRL1790 da NFKB 
ekspresyonunu arttırırken CD24 seviyesini de arttırmıştır. Fakat, Bcl2 ekspresyonunu 
etkilememiştir. NFKB ekspresyon artışına ek olarak, bu sonuçlar göstermiştir ki  
DE8 apoptoz düşmesi için başka bir yolak takip etmektedir. Bu fikir etkili 
Enterobacter suşlarının filogenetik ağaçlarının çizilmesiyle doğrulanmıştır. Etkili 
olan Enterobacter suşları filogenetik ağaçta incelendiği zaman, DE8 in diğerlerinden 
daha uzakta olduğu gözlenmiştir. 
 
 
Apoptoz inhibisyonu, bakterilerin konak hücresinde çoğalmalarına olanak sağlayan 
önemli bir patojenite mekanizmasıdır. Bazı bakteriler apoptozu indükleyebilirler, bu 
durumda ise bakterilerin hedefi kendilerini fagositozdan koruma amacıyla 
makrofajlar, nötrofiller gibi immün sistem hücreleri olmaktadır. Apoptozu inhibe 
eden pek çok bakteri suşu bulunmaktadır. Bizim çalışmamız ise apoptozun 
Enterobacter suşları tarafından inhibe edilebileceğini gösteren ilk çalışmadır. Kanser 
gelişimi için apoptoz inhibisyonu neden bu kadar önemlidir? Çünkü apoptoz farklı 
aşamalar içeren kompleks bir olaydır ve bu aşamaların herhangi birisinde olabilecek 
bir bozukluk kanserleşmeye yol açabilmektedir. Bcl2 nun apoptozu inhibe ederek 
kanserleşmeyi teşvik ettiği ve apoptoz düşmesinin kanserleşmeye sebep olduğunu 
gösteren çalışmalar bulunmaktadır. 
 
Sonuç olarak bizim çalışmamızda Enterobacter suşlarının kolon kanserine yol 
açabileceği gösterilmiştir. Bu çalışma, kolon kanseri başlangıcı ve ilerlemesinde 
Enterobacter spp. nin klinik olarak önemli bir faktör olabileceğini gösteren ilk 
çalışmadır. Tedavi için yeni stratejiler geliştirilmesine yönelik çalışmalar hayvan 
modelleriyle genişletebilinir. 
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1. INTRODUCTION 
1.1 Parts and Histology of  The Colon 
The terminal 1-1,5 m of the gastrointestinal tract is called as the colon. As shown in 
Figure 1.1, it consists of different parts named; Ascending Colon, Transverse Colon, 
Descending Colon and Sigmoid Colon (Levine and Haggitt, 1989). 
 
Figure 1.1: Diagram of the major regions of the colon (Levine and Haggitt,1989). 
The large intestine, in which water and electrolyte absorption is made, contains the  
feces. The colonic mucosa is composed of columnar epithelium covering the surface 
and lining the crypts, also lamina propria and a muscle layer the muscularis mucosae. 
The surface epithelium which is a protective barrier between the host and the luminal 
environment, is composed of absorptive and goblet cells. Absorptive cells are active 
in colonic ion and water transport. Goblet cells synthesize, store and  secrete mucous 
granules. In Figure 1.2, absorptive cells (A) and goblet cells (G) in the normal 
colonic surface epithelium, the underlying basement membrane complex (small 
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arrows) , intraepithelial lymphocytes (arrowheads) and nuclear dust in the lamina 
propria (large arrow)  is shown (Levine and Haggitt, 1989). 
 
Figure 1.2 : Normal colonic surface epithelium (Levine and Haggitt,1989). 
In the crypt epithelium in addition to mature absorptive cells and goblet cells, 
immature and undifferentiated precursor cells, endocrine and Paneth cells exist. In 
the endocrine cells hormones within the cytoplasmic secretory granules are observed. 
Paneth cells are also secretory cells. The lamina propria extends from the 
subepithelial basement membrane complex to the muscularis mucosae. The cells in 
the lamina propria are mostly active in host defense. Plasma cells (B cells) exist in 
lamina propria. T-lymphocytes exist in the lamina propria, colonic epithelium and 
submucosa. Myeloid cells including eosinophils and mast cells normally exist in the 
lamina propria. Eosinophils and mast cells may permeate the surface epithelium but 
neutrophils are not normally present in either the surface or crypt epithelium. 
Fibroblasts also exist in lamina propria as well as macrophages and neuroendocrine 
cells. Muscularis mucosae which is a thin layer of muscle, separates the mucosa 
epithelium and lamina propria from the deeper submucosa. Same as lamina propria 
the submucosa contains lymphocytes, plasma cells, fibroblasts, macrophages and 
different from lamina propria it contains fat cells. The external smooth muscles of 
the colon has 2 layers and neural tissue lies between those 2 layers. The layer of 
connective tissue between the serosa and muscularis propria constitutes the 
subserosal tissue  (Levine and Haggitt , 1989). Colonic epithelial photo was given in 
Figure 1.3 and Figure 1.4. 
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Figure 1.3:  Colonic - epithelium stained with haemotoxylin eosin. 1-tunica mucosa,              
                     2- tunica submucosa, 3-tunica muscularis propria, 4- tunica serosa, 
                     5-glands (crypts) in the lamina propria (Url-1). 
 
 
Figure 1.4: Colonic epithelial (Url-2). 
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1.2 General Knowledge About Cancer 
Cancer is a disease in which cells proliferate without regulation. As a result of 
unregulated proliferation of cells tumor formation which is defined as growing mass 
of abnormal cells occurs. If a tumor cell invade the surrounding tissues, it is defined 
as malignant, if not , the tumor is called as benign. Metastasis is the process in which 
malignant tumors spread to other locations in the body, forming secondary tumors. If 
the mechanism for apoptosis which is defined as programmed cell death, is impaired 
or inactivated, cancer may develop (Snustad and Simmons, 2006; Alberts et al., 
2002).  
According to the tissue and cell type they arise, cancers can be classified.  
Carcinomas are cancers that arise from epithelial cells, sarcomas are those that arise 
from connective tissue or muscle cells. Cancers that are derived from hemopoietic 
cells and from cells of the nervous system are called as leukemias. According to the 
structure of the tumor, the location in the body, and the specific cell type these 
categories can be subdivided. A benign epithelial tumor with a glandular 
organization is called as an adenoma and the corresponding type of malignant tumor 
is called as an adenocarcinoma. Because most of the cell proliferation in the body 
occurs in epithelia, or because epithelial tissues are most frequently exposed to the 
physical and chemical conditions that cause cancer, about 90% of human cancers are 
carcinomas.  A single cell that has an initial mutation is thought to cause the cancer 
but in order to make the cell cancerous, additional mutations whose protein products 
are involved in the control of the cell cycle, must also occur. Tumor progression, that 
takes many years, includes mutation and natural selection among somatic cells 
(Alberts et al., 2002; Snustad and Simmons, 2006). 
Products of some genes can make a cell cancerous and that can promote cell division 
is called as oncogen whereas product of a gene is involved in the repression of cell 
division and appears to prevent the formation of cancer is called as a tumor 
suppressor gene. Colon cancer is one of the most common cancer types which results 
from genetic factors such as oncogene overexpression and tumor suppressor gene 
inactivation (Alberts et al., 2002; Snustad and Simmons, 2006; Rupnarain et al., 
2004).  
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1.3 Programmed Cell Death : Apoptosis, Autophagy and Programmed Necrosis  
Apoptosis is a multi-step pathway which is responsible for cell death. It exists not 
only during development but also in adult multicellular organisms to control cell 
numbers. Cell shrinkage, chromatin condensation, nuclear and cell fragmentation are 
the main features of apoptosis (Cotter, 2009). Apoptosis can also exist as a defense 
mechanism when cells are damaged as a result of disease or noxious agents. Cell 
shrinkage and pyknosis are observed during early stage of apoptosis. As a result of 
cell shrinkage, the cell becomes smaller in size, the cytoplasm becomes dense and 
the organelles become more tightly packed. After the chromatin condensation 
pyknosis occurs. Apoptotic bodies are engulfed by phagocytic cells. No 
inflammatory reaction occurs as a result of apoptosis or removal of apoptotic cells 
because, apoptotic cells do not release their cellular constituents into the surrounding 
interstitial tissue, they are phagocytized by surrounding cells, the engulfing cells do 
not produce anti-inflammatory cytokines (Elmore, 2007). Apoptosis mechanisms are 
summarized on Figure 2.1 and Figure 2.2 
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Figure 2.1: Pathways of Apoptosis 1 (Huerta et al, 2006). 
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Figure 2.2: Pathways of Apoptosis 2 (Wong, 2011). 
There are two main apoptotic pathways; the extrinsic or death receptor pathway, the 
intrinsic or mitochondrial pathway and an additional pathway which involves T-cell 
mediated cytotoxicity and perforin-granzyme dependent killing of the cell. In the 
perforin granzyme pathway, apoptosis is induced by either granzyme A or granzyme 
B. The extrinsic, intrinsic and granzyme B pathways converge on the same terminal, 
execution pathway which is initiated by the cleavage of caspase-3. Then DNA 
fragmentation, degradation of cytoskeletal and nuclear proteins, crosslinking of 
proteins occur. Apoptotic bodies are formed, ligands for phagocytic cell receptors are  
expressed and finally they are engulfed by phagocytic cells. The granzyme A 
pathway activates caspase independent cell death pathway via single stranded DNA 
damage (Elmore, 2007). 
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Caspases cleave proteins at aspartic acid residues. Different types of caspases exist 
such as initiators (caspase-2,-8,-9,-10), effectors (caspase -3,-6,-7) and inflammatory 
caspases (caspase -1,-4,-5). In addition to those caspase -11 which regulates 
apoptosis and cytokine maturation during septic shock, caspase -12 that mediates 
endoplasmic specific apoptosis and cytotoxicity by amyloid-β, caspase-13 which is 
suggested to be a bovine gene and caspase-14 which is highly expressed in 
embryonic tissues but not in adult tissues are known. As a result of the expression 
and activation of tissue transglutaminase in apoptotic cells extensive protein cross 
linking occurs. DNA breakdown is performed by Ca
2+  
and Mg
2+ 
 dependent 
endonucleases. Another important event in apoptotic cell is the movement of the 
membrane lipid phosphatidylserine from the inner to the outer side of the plasma 
membrane. This functions as a recognition signal for phagocytic cells to engulf 
apoptotic cells (Elmore, 2007; Cotter, 2009).  
The extrinsic pathway involves transmembrane receptor mediated interactions. 
Members of the tumor necrosis factor (TNF) receptor family have cysteine rich 
extracellular domains and death domain. This death domain transmits the death 
signal from the cell surface to the intracellular signaling pathways. The best 
characterized ligands and corresponding death receptors are FasL/FasR and 
TNF-α/TNFR1. When the death ligand binds to the death receptor, binding site for 
an adaptor protein is formed and whole ligand-receptor-adaptor protein complex is 
called as the death inducing signaling complex (DISC). DISC then initiates the 
assembly and activation of procaspase 8. The activated caspase 8 initiates apoptosis 
by cleaving other caspases (Elmore, 2007; Wong, 2011). 
Cytotoxic T lymphocytes can kill target cells using the extrinsic pathway and 
FasL/FasR interaction. But also another pathway is used against tumor cells and 
virus-infected cells in which the transmembrane pore forming molecule perforin is 
secreted with a subsequent exophytic release of cytoplasmic granules through the 
pore and into the target cell. These granules possess serine proteases such as 
granzyme A and granzyme B. Granzyme B cleave proteins at aspartate residues and 
activate procaspase-10. Mitochondrial pathway and direct activation of caspase-3 are 
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also utilized by granzyme B. Granzyme A is important in cytotoxic T cell induced 
apoptosis and activates caspase independent pathway (Elmore, 2007). 
The intrinsic pathway is initiated within the cell. Genetic damage, hypoxia, 
extremely high concentrations of cytosolic Ca
2+
 and oxidative stress are some of the 
factors that activate the intrinsic mitochondrial pathway. Increase in mitochondrial 
permeability and the release of proapoptotic molecules such as cytochrome-c into the 
cytoplasm are the main features. This pathway is regulated by a group of proteins 
which belongs to the Bcl-2 family. Bcl-2 proteins are divided into 2 groups such as 
proapoptotic proteins (Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim and Hrk) and the 
antiapoptotic proteins (Bcl-2, Bcl-XL, Bcl-W, Bfl-1 and Mcl-1). While the 
antiapoptotic proteins block the mitochondrial release of cytochrome-c, the 
proapoptotic proteins promote such release. The balance between those two groups 
of proteins determines whether the apoptosis would be initiated. Other apoptotic 
factors are apoptosis inducing factor (AIF), second mitochondria-derived activator of 
caspase (Smac), direct IAP Binding protein with Low pI (DIABLO), and Omi/high 
temperature requirement protein A (HtrA2). As a result of the release of cytochrome-
c to the cytoplasm, a complex which is made up of cytochrome c, Apaf-1 and 
caspase 9 is formed and this activates caspase 3. Smac/DIABLO or Omi/HtrA2 
promotes caspase activation by binding to inhibitor of apoptosis proteins (IAPs) 
which leads to disruption in the interaction of IAPs with caspase-3 or caspase -9 
(Wong, 2011). 
In the execution phase of apoptosis, a series of caspases are activated. Caspase 9 is 
the upstream caspase in the intrinsic pathway whereas caspase 8 in extrinsic 
pathway. Both pathways converge to caspase 3. Then the inhibitor of the caspase 
activated deoxyribonuclease which is responsible for nuclear apoptosis is cleaved by 
caspase 3. Downstream caspases induce cleavage of protein kinases, cytoskeletal 
proteins, DNA repair proteins and inhibitory subunits of endonucleases family. 
These also have effects on the cytoskeleton, cell cycle and signaling pathways 
(Wong, 2011). 
There is one more pathway in apoptosis which is not well known and called as the 
intrinsic endoplasmic reticulum pathway. It is caspase-12 dependent and 
mitochondria independent. As a result of cellular stresses such as hypoxia, free 
radicals or glucose starvation the ER is injured and unfolding of proteins, reduced 
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protein synthesis occurs, then activation of caspases is performed by dissociation of 
an adaptor protein known as TNF receptor associated factor 2 (TRAF2) from 
procaspase-12 (Wong,2011). 
Autophagy is a catabolic process in which recycling occurs. It can also be accepted 
as a primary degradation way for long lived proteins. It is observed in many 
eukaryotic cell types, where organelles and other cell components are degraded by 
lysosomes. Lysosome is a cellular compartment, which possess hydrolases. These 
hydrolases can cleave proteins, lipids, nucleic acids, and carbohydrates. 
Autophagosome formation is the first step in this process. A double membrane 
vacuole engulfs a portion of the cytoplasm to form this structure. The double 
membrane is obtained from ribosome-free areas of rough endoplasmic reticulum. 
Then autophagosomes fuse with lysosomes to form autolysosomes. Digestion of the 
cellular components lead to amino acids and fatty acids generation which can be used 
for either protein synthesis or can be used for ATP production after they are oxidized 
by the mitochondrial electron transport chain in order to survive the cell under 
starvation conditions. It is a mechanism that is activated as a result of extra- or 
intracellular stress, and can result in cell survival. Autophagy can also lead to cell 
death if it is overactivated. Autophagic cell death is caspase independent. In cells 
grown in presence of caspase inhibitors or in cells that possess defects in apoptosis 
system, autophagic death is demonstrated. Chromatin condensation, membrane 
blebbing are also observed in autophagy but there is no DNA fragmentation or 
apoptotic bodies (Ouyang et al, 2012; Sun and Peng, 2009; Guimaraes and Linden, 
2004). 
Programmed necrosis occurs as a result of several signaling pathways. The 
differences of the programmed necrosis from other programmed cell death 
mechanisms are the lack of caspase and lysosomal involvement. Main features of this 
process are the swelling of intracellular organelles such as mitochondria, ER and 
Golgi apparatus and loss of the plasma membrane integrity. As a result of signaling 
or damage induced lesions, mitochondrial dysfunction, enhanced generation of 
reactive oxygen species, ATP depletion and proteolysis by calpains and cathepsins 
are observed. Programmed necrosis is also associated with nuclear degradation  (Sun 
and Peng, 2009). 
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Mitochondria are not only an energy factory of living cells but also they trigger or 
amplify the signals that are required for cell death. Cell death by apoptosis is related 
with mitochondrial membrane permeabilization. In addition to the induction of the 
permeability transition in the inner mitochondrial membrane, the release of 
cytochrome c, Smac/Diablo, AIF and endonuclease G may also exist in mitochondria 
dependent apoptosis. Researches show that mitochondrial permeabilization also 
occurs in autophagy and necrosis and cells behave against mitochondrial 
permeability transition (MPT) in a graded manner. Autophagy is activated when 
MPT occurs only in a few mitochondria, apoptosis is observed when a large number 
of mitochondria is permeabilized. It can be because of the higher concentration of 
molecules such as cytochrome c and AIF in the cytoplasm. Necrosis is promoted 
when all of the mitochondria in the cell are affected (Guimaraes and Linden, 2004). 
Forms of cell death are shown in Figure 2.3. 
 
Figure 2.3 : Forms of Cell Death (Guimaraes and Linden, 2004). 
1.4 Programmed Cell Death and Cancer 
Under extreme conditions it is known that autophagy is effective in cell survival 
because it provides the energy required by the cells for their minimal functions when 
nutrients are scarce by degradation of intracellular macromolecules. Thus, in early 
stages of cancer progression, autophagic activation can play a protective role. By 
activating proautophagic genes and blocking antiautophagic genes in oncogenesis, 
autophagy can work as a tumor suppressor. However, autophagy can also take part in 
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carcinogenesis as a pro-tumor process, by regulating several pathways including 
Beclin-1, Bcl-2, Class III and I PI3K, mTORC1/C2 and p53. Necrosis was 
previously accepted as an accidental death but studies proved that it is controlled. 
Receptor interacting protein (RIP) kinases, poly (ADP-ribose) polymerase-1 
(PARP1), NADPH oxidases and calpains are involved in programmed necrosis. 
When cells are necropsied, integrity of the cell membrane is destroyed, and 
intracellular materials are released leading to inflammatory responses by immune 
cells.  As a result of the inflammation, tumor growth may be promoted (Ouyang et al, 
2012). 
Studies showed that apoptosis reduction or resistance is effective in carcinogenesis. 
The mechanisms for apoptosis evasion and carcinogenesis are ; balance disruption of 
proapoptotic and antiapoptotic proteins, reduction of caspase function and 
impairment of death receptor signaling. Bcl2 family of proteins is important in 
apoptosis regulation. When there is disruption in the balance, dysregulated apoptosis 
occurs. The p53 protein, coded by gene TP53, located at the short arm of 
chromosome 17, is the mostly known tumor suppressor protein. It is involved in 
many processes such as cell cycle regulation, development, differentiation, gene 
amplification, DNA recombination, chromosomal segregation, cellular senescence 
and induction of apoptosis. Oncogenic property of this gene occurs as a result of a 
mutation. Defects in p53 gene are related with more than 50% of human cancers. p53 
regulated the expression of BAX in both in vitro and in vivo systems. It also controls 
the expression of Bcl2 family proteins. The inhibitor of apoptosis proteins (IAPs), 
which are a group of proteins that regulate apoptosis, cytokinesis and signal 
transduction, are inhibitors of caspases. Their main feature is the presence of a 
baculovirus IAP repeat (BIR) protein domain. They inhibit caspase activity by 
binding their conserved BIR domains to the active sites of caspases and by 
promoting degradation of active caspases or by keeping the caspases away from their 
substrates. In many cancers dysregulation in IAP expression is observed. Caspases 
which are classified in two groups such as the ones related to caspase 1 (caspase-1, 
-4,-5,-13,-14) that are functional during inflammation by cytokine processing, and 
the ones that are effective in apoptosis (caspase -2, -3, -6, -7, -8, -9, -10). Apoptosis 
related caspases are also divided into two groups such as initiator caspases (caspase  
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-2, -8, -9, -10) that are functional in initiation of apoptosis and effector caspases 
(caspase -3, -6, -7) that act by cleaving cellular components during apoptosis. Low 
levels of caspases or defects in caspase function are related with a decrease in 
apoptosis and carcinogenesis. Death receptors such as TNFR1(DR1), Fas (DR2, 
CD95, APO-1), DR3(APO-3), DR4 [TNF related apoptosis inducing ligand receptor 
1 (TRAIL-1) or APO-2], DR5 (TRAIL-2), DR6, ectodysplasin A receptor (EDAR) 
and growth factor receptor (NGFR) have a death domain. As a result of a death 
signal, molecules go to the death domain and a signaling cascade is activated. 
Abnormalities like down regulation of the receptor, impairment of receptor function, 
reduced level in death signals all lead to apoptosis reduction (Wong, 2011; Cotter, 
2009). 
The mechanisms that are effective on apoptosis during cancer is summarized in 
Figure 2.4. 
 
Figure 2.4: Apoptosis mechanisms during cancer (Wong, 2011). 
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1.5 Colorectal Cancer and Molecular Pathways  
Cancer in colon and rectum have different types. Among them are carcinoid tumors 
which start from specialized hormone-producing cells in the intestine, 
gastrointestinal stromal tumors that start from specialized cells in the wall of the 
colon called the interstitial cells of  Cajal. These types of tumors are either benign or 
malignant. They can be found anywhere in the digestive tract, but are unusual in the 
colon. Lymphomas start in lymph nodes, but they can also start in the colon. 
Sarcomas are tumors that can start in blood vessels, connective tissue, in the wall of 
the colon and rectum. Sarcomas are rare in colon and rectum.                               
More than 95 % of colorectal cancers are adenocarcinomas (Url-3). Progression of  
colon cancer is shown in Figure 3.1.  
 
Figure 3.1: Progression of Colon Cancer (Url-4). 
Colorectal cancer exists in the epithelium lining the colon and rectum.  The first 
stage is the polyp formation. These polyps are accepted as the precursors of most 
colorectal cancers. Then tumor cells become invasive, break through the epithelial 
basal lamina, spread through the muscle and finally metastasize to lymph nodes, liver 
and other tissues. Hereditary Colorectal Cancer Syndromes result from mutations in 
genes involved in colorectal carcinogenesis. Approximately 5% of colorectal cancers 
are in this group. Familial Adenomatous Polyposis is more common. Adenomatous 
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Polyposis Coli gene is a tumor suppressor gene which is located on chromosome 
5q21. It has 15 exons and encodes a 310 kDa protein with multiple functional 
domains. APC  protein regulates epithelial homeostasis and degradation of 
cytoplasmic β-catenin. Wnt signaling pathway which is an important signal 
transduction pathway in colon cancer includes APC and β-catenin. APC protein is an 
inhibitory component in this pathway. Firstly in colon cancer, mutations arm of 
chromosome 5 appear. When APC mutation occurs, cytoplasmic β-catenin 
accumulation  is observed and then it binds to the Tcf family of transcription factors. 
When it binds to β-catenin, activation of TCF4 which stimulates growth of the  
colonic epithelium when it has β-catenin bound to it, is prevented. Depletion of the 
gut stem cell population is observed as a result of  loss of  TCF4, so that loss of the 
antagonist APC can cause overgrowth by the opposite effect. In another words, in the 
Wnt pathway, APC binds to  β-catenin  and induces its degradation. When APC 
function is lost as a result of mutation or promoter methylation, cytoplasmic β-
catenin  is accumulated which leads to nuclear translocation, and binding of β-
catenin to T-cell  factor  (TCF) / Lymphoid enhancer factor (LEF) Alteration exists 
in expression of several genes that affects proliferation, differentiation, migration and 
apoptosis. APC gene is also important in controlling cell cycle progression, 
stabilizing microtubules and promoting chromosomal stability. These mutations can 
be observed both in small benign polyps and malignant tumors. Generally, 
progression of polyps into lethal cancers requires additional mutations. As a result of 
the inactivating mutations in APC gene the rate of cell proliferation in the colonic 
epithelium increases. Abnormal tissues within the intestinal epithelium which 
contain dysplastic cells that are defined as cells with unusual shapes and enlarged 
nuclei develop. Then those abnormal tissues grow to form early stage adenomas. 
Among the few colorectal tumors that lack APC mutation, has a high proportion of 
activating mutations in β-catenin instead. So, that shows that WNT signaling 
pathway is one of the major pathways that is critical for cancer. It is especially 
important for initiation and progression of colorectal cancer. SMAD4 gene mutations 
are also reported in 30% of colon cancers.  If the K-ras proto-oncogene is activated 
in one of these adenomas, that adenoma may grow and develop more fully. The K-
ras gene codes for a 21kDa protein that is activated by extracellular signals. Because 
of the impaired GTPase activity which hydrolyses GTP to GDP, the mutated protein 
is locked in the active form. Mostly activating mutations are found in codons 12 and 
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13 of exon 1. Multiple cellular pathways that control cellular growth, differentiation, 
survival, apoptosis, cytoskeleton organization, cell motility, proliferation and 
inflammation are affected by  Ras activation. After the adenoma formation, to induce 
it to progress further, inactivating mutations in tumor suppressor genes located in the 
long arm of the chromosome 18 occur. In order to transform this late adenoma into 
carcinoma p53 tumor suppressor gene on chromosome 17, should also be inactivated. 
Those carcinoma cells invade other tissues in presence of additional inactivation 
mutations in other tumor suppressor genes. p53 tumor suppressor gene mutations are 
common in colon cancer but occur late in tumorigenesis. It is suggested that p53 did 
not restrict the proliferation of DNA damaged cells, but induce apoptosis in response 
to mutations of APC and ras and p53 is inactivated at a late stage of tumor 
development (Alberts et al, 2002; Snustad and Simmons, 2006; Rupnarain et al, 
2004; Roncucci and Ponz de Leon, 2000;  Sohaily et al, 2012).  
In MYH-Associated Polyposis (MAP), colorectal adenomatous polyps are formed. 
This is an autosomal recessive disorder in which bi-allelic mutations occur in the 
MYH gene, located on chromosome 1p35. MYH gene is a base excision repair gene 
that targets oxidative DNA damage. In this type of colorectal cancer, APC mutations 
also exist and in addition to this low frequency of loss of heterozygosity (LOH) is 
observed. Hereditary Non Polyposis Colorectal Cancer caused by mutations in DNA 
mismatch repair (MMR) genes which lead to replication errors and high potential for 
cancer. Chromosomal instability is the most common cause of genomic instability in 
colorectal cancer. Gain or loss of whole chromosomes or chromosomal regions is 
observed in this pathway. Imbalance in chromosome number, chromosomal genomic 
amplifications and a high frequency of loss of heterozygosity exists. Another 
pathway in colorectal cancer is the microsatellite instability pathway. Microsatellites 
are short repeat nucleotide sequences which spread over the whole genome and 
because of their repetitive manner, they cause errors in replication. During 
replication DNA mismatch repair system (MMR) normally recognizes and repairs 
base-pair mismatches but as a result of the microsatellite instability mismatch repair 
system becomes inable to correct the errors. In CpG Island Methylator Phenotype 
pathway, DNA methylation and as a result of this gene silencing occurs in tumor 
suppressor genes. In humans, epigenetic changes are caused by DNA methylation or 
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histone modifications. DNA methylation usually occurs at the 5'-CG-3' (CpG) 
dinucleotide (Sohaily et al, 2012).  
Differences between sporadic colon cancer and colitis associated colon cancer is 
shown in Figure 3.2 below. 
 
Figure 3.2 : Molecular Pathogenesis of Colon Cancer (Ullman and Itzkowitz, 2011). 
1.6 Colitis Associated Colorectal Cancer 
Researches demonstrated that patients with ulcerative colitis and Crohn’s disease 
have high risk for colorectal cancer. Duration and anatomic extent of colitis increases 
the risk. Chromosome instability, microsatellite instability and DNA 
hypermethylation which lead to sporadic colorectal cancer, are also observed in 
colitis associated colorectal cancer. In inflammed colonic mucosa, unlike the normal 
colon mucosa, these genetic alterations occur before any histologic evidence of 
dysplasia or cancer (Ullman and Itzkowitz, 2011). The dysplastic precursor in 
sporadic colon cancer is an adenoma which is a discrete focus of neoplasia that can 
be removed by endoscopic polypectomy whereas in Inflammatory Bowel Disease 
dysplasia is polypoid or flat, localized, diffuse or multifocal and the most important 
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point is that once it is found the entire colon is at high risk of neoplasia, therefore 
surgical removal of the entire colon and rectum is required for treatrment (Itzkowitz 
and Yio, 2004). 
It is found in the studies that colitis associated colorectal cancer occurs at a younger 
age than the general population. The molecular alterations that exist in Sporadic 
Colorectal Cancer can also be observed in Colitis Associated Colorectal Cancer. It is 
reported in studies that the frequency of chromosomal instability and microsatellite 
instability is roughly the same as in Sporadic Colorectal Cancer. However, it is also 
reported that differences exist in timing and frequency of these alterations (Itzkowitz 
and Yio, 2004; Willenbucher et al, 1999). APC mutation (loss of function) which is a 
common event and occurs at an early step in sporadic colon cancer, is a less frequent 
event and occurs late in colitis associated colon cancer. In colitis, p53 mutations 
occur at an early stage even before dysplasia. Also most of the p53 mutations were 
observed in inflammed mucosa deriven from ulcerative colitis patients without 
cancer, which makes us think that chronic inflammation itself might induce these 
mutations. Allelic deletion of p53 exists in almost 50%-85% of colitis associated 
colon cancer. Methylation is also important in development and progression of colitis 
associated cancer. Methylation of CpG islands in several genes is observed in colitis 
patients. Inflammation also acts on colon carcinogenesis by oxidative stress 
production which causes cellular damage that leads to colitis and colon cancer. As a 
result of inflammation, reactive oxygen and nitrogen species are produced by 
macrophages and other leukocytes, which causes mutations that result in tumor 
initiation. The mismatch repair system is inactivated by  hydrogen peroxide. 
Leukocytes and other types of immune cells that compose the tumor inflammatory 
microenvironment are responsible from the breakage of the basement membrane 
which is required for the invasion and migration of tumor cells. Neutrophils, 
eosinophils, dendritic cells, mast cells and lymphocytes are also functional in 
epithelial-originated tumors.   Angiogenesis, which is an important process in tumor 
progression, is also found related to chronic inflammation (Itzkowitz and Yio, 2004; 
Ullman and Itzkowitz, 2011; Lu et al, 2006). Initiation of Sporadic Colon Cancer and 
Colitis Associated Colon Cancer is shown in Figure 3.3. 
 
19 
 
 
Figure 3.3: Initiation of Sporadic and Colitis- Associated Colon Cancer 
       (Terzic et al, 2010). 
1.7 Bacteria and Cancer 
Environmental factors, such as meat, saturated fat, low physical activity, obesity, 
smoking and alcohol beverages are also reported as the causes that increase the 
colorectal cancer risk. In the previous studies, a strong relationship between 
inflammatory diseases and colon cancer has also been reported. It was shown that 
patients with ulcerative colitis, Crohn’s disease and inflammatory bowel diseases had 
increased risk for colorectal cancer (Roncucci and Ponz de Leon, 2000).  
Recently, different studies have been performed to clarify the relationship between 
bacteria and cancer. Helicobacter pylori is well known to be associated with gastric 
cancer and Salmonella  typhi, Echerichia coli and Chlamydia pneumoniae are the 
organisms that are associated with gall bladder, colon and lung cancer, respectively. 
Streptococcus bovis is defined as a low grade pathogen that is involved in bacteremia 
and endocarditis. Existance of a relationship between Streptococcus bovis and colon 
cancer was also determined (Mager, 2006; Biarc et al, 2004). It was shown that 
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Bartonella spp., Lawsonia intracellularis and Citrobacter rodentium infections can 
induce cellular proliferation which can be reversed by antibiotic treatment (Lax and 
Thomas, 2002). Small intestinal lymphomas and ocular lymphomas were found to be 
linked to Campylobacter jejuni and Chlamydia psittaci infections, respectively. In 
each case, it was shown that antibiotic treatment could eradicate the disease at an 
early stage (Lax, 2005). In animal models, it was found that Citrobacter freundii 
developed colonic hyperplasia and when exogenous mutagens were applied, 
malignancy occured more rapidly than the uninfected ones (Parsonnet, 1995). 
Enterococcus faecalis, another intestinal commensal, developed colitis and tumors in 
IL-10 knockout mice (Huycke and Gaskins, 2004).   
Studies also showed that several bacterial toxins interfere with cellular signalling 
mechanisms in a way that is characteristic of tumour promoters, they can disrupt 
cellular signalling to perturb the regulation of cell growth or to induce inflammation. 
Proliferation, apoptosis and differentiation processes are affected by those toxins. 
Some of those, directly damage DNA by enzymatic attack, these are the toxins that 
mimic carcinogens and tumour promoters. Pasteurella multocida toxin that acts as a 
mitogen and Escherichia coli cytotoxic necrotizing factor (CNF) which activates all 
members of the Rho family of small GTPases can be given as an example. In this 
way, signalling components that are downstream of Rho such as COX2 which is 
involved in different stages of  tumour development including inhibition of 
apoptosis, is stimulated. Bacterial products can also affect DNA repair mechanisms. 
Bacteroides fragilis toxin is another one that leads to cell proliferation. According to 
the studies on mice it was also reported that Citrobacter rodentium infection caused a 
colonic hyperplastic disease that could lead to colonic cancer (Lax, 2005; Lax and 
Thomas, 2002). 
1.8 Enterobacter species 
Enterobacter strains are gram negative, opportunistic and increasingly important 
nasocomial pathogens. They are a member of the family Enterobacteriaceae. 
Enterobacter aerogenes and Enterobacter cloacae are the most frequently 
encountered human pathogens among this genus. As a gram negative organism they 
possess endotoxin. In some Enterobacter species, Shiga-like toxin production has 
also been observed. The great resistance to disinfectants and antimicrobial agents 
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make these pathogens available to cause nasocomial infections (Sanders and Sanders, 
1997; Bilgehan, 2000). 
1.9 Purpose of Thesis 
Many studies have been performed to determine the interaction between bacteria and 
cancer. However, there has been no attempts to demonstrate a possible relationship 
between Enterobacter spp. and colon cancer. Therefore, in the present study, it was 
aimed to investigate the effects of Enterobacter group of microorganisms on colon 
cancer. Determination of the interaction between strains of Enterobacter spp. and 
colon cancer will lead to new approaches to colon cancer initiation and mechanism. 
Identification of a possible interaction between colon cancer and strains of 
Enterobacter spp. may also be for development of prophylaxis and new treatment 
strategies. 
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2. METHODS   
2.1 Isolation of  Enterobacter strains   
Total thirteen bacterial strains were used in this study. Two strains of Enterobacter 
spp. and one strain of Escherichia coli were isolated using Sheep Blood Agar from 
patients who were treated at Istanbul University, Istanbul Faculty of Medicine, 
Department of General Surgery. Eight strains of Enterobacter spp. and one strain of 
Morganella morganii were provided from Marmara University, School of Medicine, 
Department of Medical Microbiology. In addition, an environmental strain of 
Enterobacter spp. was obtained from Microbial Collection Unit at Yeditepe 
University, Genetics and Bioengineering Department. 
2.2 Identification of  Bacteria by FAME profile analysis  
Bacterial strains were identified by FAME profile analysis. Fatty acids exist in lipids 
in biological membranes including phospholipids, glycolipids and/or 
lipopolysaccharides. Fluidity, integrity and permeability of the membrane and the 
activities of membrane-bound enzymes are the properties that are influenced by fatty 
acids. Fatty acids differ in phylogenetically different microorganisms, mainly in the 
concentration and composition such as chain length, double-bound positions and 
substitutions. But in closely related organisms they are found similar, and under 
standardized conditions they remain constant. MIDI (Microbial Identification 
System) is a system that identifies and classifies microorganisms according to their 
fatty acid profiles. In order to isolate the fatty acids a single colony of the 
microorganism to be tested was inoculated by streaking on TSA ( Tryptic Soy Agar) 
and was incubated about 24h at 37 °C.  After the incubation period, the 
microorganism was harvested from the third and the fourth quadrant and transferred 
to a sterile 13mm x 100 mm screw cap glass tube. Using a four stepped procedure 
fatty acids were isolated and then fatty acid methyl esters were gained. Stock 
reagents to isolate the fatty acids were prepared according to Table 1. Then  1 ml 
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Saponification Reagent was added , after vortexing for 5-10 sec it was incubated at 
100 °C for 5 min. Again vortexing was done for 5-10 sec. and was incubated at 100 
°C for 25 min. After the incubation cooling was done. Methylation was performed by 
adding 2 ml Methylation Reagent and vortexing for 5-10 sec, and then it was 
incubated at 80 °C for 10 min. Rapidly cooling was done after the incubation. For 
extraction, 1.25 ml Extraction Solvent was added and incubated for 10 min at rotator. 
Then bottom phase was removed and top phase was saved. For purification, base 
wash was done and finally 2/3 top phase was transferred to GC vials. Using a fused-
silica capillary column (25m by 0.2mm) with cross-linked 5% phenylmethyl silicone, 
gas chromatography was performed. Calibration standard mix, that contains nC9-
nC20 saturated, 2 and 3 hydroxy fatty acids, were used to identify the peaks and to 
check the column performance. Identification of the fatty acids were performed by 
equivalent chain length data. Identity of the unknown strain was determined by 
comparing the FAME profiles, to those that exist in the standard libraries in the MIS 
software package  (Şahin, 2001; Buyer, 2002; Agilent-Sherlock MIS Operating 
Manual, 2005).   
Table 1.1: Reagents required for fatty acid isolation. 
REAGENT 
 
CONTENT 
1.Saponification Reagent Sodium hydroxide                      45g 
Methanol                                    150 ml 
Deionized distilled water          150 ml 
2.Methylation Reagent 6.00N Hydrochloric Acid         325 ml 
Methanol                                   275ml 
3.Extraction Solvent Hexane                                      200ml 
Methyl tert-butyl ether             200 ml 
4.Base Wash Sodium hydroxide                    10.8 g 
Deionized distilled water          900 ml 
2.3 Microbial Identification by Metabolic Activities 
VITEK2 (Biomerieux) is an automatic system which makes identification and 
antimicrobial susceptibility testing in a few hours according to metabolic changes 
(Perez-Vazkuez et al, 2001). With colorimetric reagent cards, hardware and software 
systems, it becomes a useful instrument for microbial identification. Reagent cards 
used, have wells that contain different substrates, which can measure metabolic 
activities including acidification, alkalinization, enzyme hydrolysis and growth in 
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presence of inhibitory substances.  From 24 h pure bacterial cultures, bacterial 
suspensions which were prepared in sterile saline according to Mac Farland 
Turbidity Range  0.50 - 0.63 for Gram Negatives, were measured by a turbidity 
meter and then were transferred to appropriate card of the system. Test substrates on 
Gram Negative card were shown in Table 1.2. After incubation for maximun 10 
hours, results were obtained (Jin et al, 2011; Pincus, H.D ).  
      Table 1.2: Test substrates on Gram Negative card (Pincus, D). 
Test  Mnemonic 
Ala-Phe-Pro-Arylamidase APPA 
Adonitol ADO 
L-Pyrrolydonyl-Arylamidase PyrA 
L-Arabitol IARL 
D-Cellobiose dCEL 
 Beta-galactosidase BGAL 
H2S Production H2S 
Beta-N-acetyl-glucosaminidase BNAG 
Glutamyl Arylamidase pNA AGLTp 
D-glucose dGLU 
Gamma-glutamyl-transferase GGT 
Fermentation / Glucose OFF 
Beta-glucosidase BGLU 
D-maltose dMAL 
D-mannitol dMAN 
D-mannose dMNE 
Beta-xylosidase BXYL 
Beta-alanine arylamidase pNA BAlap 
L-Proline Arylamidase ProA 
Lipase LIP 
Palatinose PLE 
Tyrosine Arylamidase TyrA 
Urease URE 
D-sorbitol dSOR 
Saccharose/ Sucrose SAC 
D-tagatose dTAG 
D-trehalose dTRE 
Citrate (sodium) CIT 
Malonate MNT 
5-Keto-d-gluconate 5KG 
L-lactate alkalinisation ILATk 
Alpha-glucosidase AGLU 
Succinate alkalinisation SUCT 
Beta-N-acetyl galactosaminidase NAGA 
Alpha-galactosidase AGAL 
Phosphatase PHOS 
Glycine Arylamidase GlyA 
Ornithine Decarboxylase ODC 
Lysine Decarboxylase LDC 
Decarboxylase Base ODEC 
L-Histidine assimilation IHISa 
Coumarate CMT 
Beta-glucoronidase BGUR 
O/129 Resistance (comp. Vibrio) O129R 
Glu-Gly-Arg-Arylamidase GGAA 
L-Malate assimilation IMLTa 
ELLMAN ELLM 
L-lactate assimilation ILATa 
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2.4 16 S rDNA Sequence Analysis 
To confirm the FAME pofile analysis and biochemical test results, the bacterial 
strains that were found as effective in the study, were also identified using 16 S 
rDNA sequence analysis. In this technique first genomic DNA was isolated from the 
bacterial strains and was controlled by agarose gel electrophoresis, then 16S rRNA 
coding region was amplified by PCR. After purification of the PCR products, 
sequencing was performed and the results were evaluated using databases (Weisburg 
et al, 1991).  
2.4.1 Genomic DNA isolation 
Bacterial Genomic DNA was isolated using QiAcube System. First bacteria was 
inoculated onto agar medium (Sheep Blood Agar or LB Agar) After incubation for 
24h, bacteria was collected and washed using PBS then was centrifugated, the 
supernatant was removed and the pellet was run according to the QiAcube Bacterial 
Pellet Protocol. 
2.4.2 Agarose gel electrophoresis 
1% (w/v) Agarose gel was prepared using TBE Buffer. Electrophoresis was carried 
out at 100 V for 20 minutes. 
2.4.3 Amplification of 16S rDNA sequencing and phylogenetic analysis of 
bacterial strains 
16S rDNA  was amplified using universal primers (27F: 
AGAGTTTGATCCTGGCTCAG, 1492R: ACGGCTACCTTGTTACGACTT) 
(Weisburg et al, 1991). PCR mix was prepared and PCR was carried out. After PCR, 
samples were controlled in 1% agarose gel and then were purified using Roche PCR 
purification kit. Using these purified samples sequencing was performed at 
REFGEN. Sequence results were evaluated by the help of databases. For 
phylogenetic analysis SDSC Biology Workbench was used (Higgins et al, 1992; 
Thompson et al, 1994; Felsenstein, 1989). 
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2.5 Isolation of bacterial proteins  
In order to minimize the chance to lose the enzymatic activity, bacterial protein was 
isolated using Easylyse bacterial protein extraction solution. For this purpose, first 
bacteria was grown in Brain Heart Broth, after 24h bacterial pellet was frozen at - 
20° C. Then pellet was resuspended in a solution containing 1 M MgCl2, Lysis buffer 
and enzyme mix and was incubated for 5 minutes at room temperature. After 
centrifugation steps finally the clear supernatant was transferred to a new tube and 
protease inhibitor coctail was added to the sample. Protein concentration was 
determined by Bradford Assay. This assay was performed in 96 well plates. Protein 
standards that were ranging from 0,1-1.5 mg/ml were prepared using BSA. 250 μl of 
the Bradford Reagent was transfered onto each well being used.  5 μl of protein 
standards, 5 μl of water as blank and 5 μl of bacterial protein samples were added 
onto separate wells. After 10 min. of  incubation at room temperature absorbance at 
590 nm. was measured using an ELISA plate reader. According to the absorbance 
values of  BSA the standard curve graph was prepared and the bacterial protein 
concentration was calculated. 
2.6 Cell culture 
NCM 460 and CRL1790 cell lines that were provided from Incell and ATCC, 
respectively were used in this study. NCM cell lines were cultured in M3 base 
medium A that was supplemented with 10% FBS and CRL1790 cell line was 
cultured in EMEM including 10% FBS and 1% PSA.  Cell lines were incubated at 
37°C in a humidified environment with 5% CO2 . 
2.7 Determination of the optimum protein concentration to apply onto cell lines        
and examination of cell proliferation 
To determine the optimum protein concentration to apply onto the epithelial cell 
lines and examine the cell proliferation, MTS assay was performed. MTS is a 
tetrazolium compound which is bioreduced by cells into a formazan product. Using 
dehydrogenase enzymes, metabolically active cells produced NADPH or NADH 
which performed this conversion (Berridge and Tan, 1993; Cory et al, 1991; Riss and 
Moravec, 1992). 
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Firstly in this test, according to the growth properties of cell lines 8000- 22000 cells 
were seeded on 96 well plates  Bacterial proteins at concentrations ranging from 2μg-
15μg were applied onto cell lines. After incubation for 72h, the medium containing 
the bacterial proteins was removed and fresh medium containing MTS was added 
and incubated for 1-4 hours. Absorbance at 490 nm was measured using ELISA 
Reader. The quantity of formazan product was directly proportional to the number of  
living cells in culture (Berridge and Tan, 1993; Cory et al, 1991; Riss and Moravec, 
1992). Same procedure was applied for negative control (NC) which contained only 
growth medium and for positive control (PC) which contained DMSO. All the 
experiment was repeated four times. The concentration which had the highest cell 
viability was determined as optimum. Using the Cell viability – Concentration 
graphs, evaluation of the cell proliferation was performed. 
2.8 Detection of Apoptosis and Cell Viability Assays 
In apoptotic cells, the membrane phospholipid phosphatidylserine exposure occurs to 
the external cellular environment. Annexin is a Ca+
2
 regulated phospholipid binding 
and membrane-binding protein. In the presence of physiological concentrations of  
Ca+
2
,  Annexin V has a high affinity for negatively charged phospholipids and thus it 
binds to cells with exposed phosphatidylserine. Because Annexin V is conjugated 
with FITC, detection could be performed using flow cytometry. Pi was used together 
with annexin to determine if the cells are early apoptotic, late apoptotic, necrotic or 
viable. Viable cells could not be stained with pi due to the intact membrane but dead 
and damaged cells could be stained (BD Technical data sheet, Niu and Chen, 2010; 
Elmore, 2007; Rescher and Gerke, 2004; Dillon et al, 2000).  
To detect apoptosis using annexin V, first of all, bacterial proteins at appropriate 
concentrations were applied onto cell lines that were seeded on 6-well plates. After 3 
days of incubation, bacterial proteins were removed, cell lines were washed and 
trypsinized and then were mixed with annexin antibody and pi. The mixture was 
incubated for 10 min. Then PBS was added and the mixture was centrifugated. After 
centrifugation the supernatant was removed, the pellet was resuspended in PBS and 
was run in flow cytometry. The same steps were also repeated for cell lines without 
bacterial protein application and also sample without annexin or pi and samples 
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containing only annexin, and only pi were run as negative and as controls, 
respectively.  
2.9 Detection of CD24  
CD24, a molecular marker of malignant tumors, was detected by flow cytometry in 
CRL1790 and NCM460 cell lines before and after bacterial protein application. In 
order to do this, first of all cell lines were seeded in 6 well plates in appropriate 
medium that was previously described. Then the total bacterial proteins at the 
optimum concentration were applied onto the cell lines and were incubated for 3 
days. After this, the proteins were removed, cell lines were washed and trypsinized 
and were mixed in PBS with conjugated CD24 antibody. Samples were incubated at 
+4°C for 1 hour. After the incubation PBS was added to the tubes and they were 
centrifugated at 1000 rpm for 5 min. The supernatant was removed and then PBS 
was added onto the pellet. Finally pi was added and after 5 min. of incubation CD24 
and pi was measured by flow cytometry. Same procedure was applied for Isotype 
which was used to measure background signal. To calculate CD24 level, Isotype 
values were extracted from the CD24 values (Sagiv et al, 2006; Han and Nair, 1995; 
Lim, 2005). 
2.10 Detection of COX-2 
COX-2 is an enzyme that acts in prostaglandin synthesis. It inhibits apoptosis by 
increasing Bcl2 expression through the mitogen activated protein kinase or 
phosphoinositide 3-kinase-AKT signaling pathways (Terzic et al, 2010). 
The samples which increased CD24 level and at the same time decreased apoptosis 
in CRL1790 cell lines and for NCM 460 cell lines again the samples that apoptosis 
reduction occurred were included in this assay. To detect COX-2, Western Blotting 
technique was used.  Bacterial protein was applied onto cell lines that were seeded on 
6-well plates. Also samples from both of the cell lines without bacterial protein 
application were tested. After 3 days of incubation, cells were washed with DPBS . 
Then whole cell lysate was obtained by addition of complete RIPA buffer which 
contains protease inhibitor cocktail, PMSF and sodium orthovanadate.  Cell lysates 
were collected using a cell scraper. Then samples were sonicated on ice with a probe 
sonicator and were stored at - 80°C. Same procedure was also applied for cell lines 
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without bacterial protein application. To determine the protein concentration Protein 
Content Assay was performed. Protein samples were diluted in distilled water. 
Bradford assay was done using Biorad Protein reagent. Protein concentration was 
calculated using the standard curve graph which was prepared according to the 
absorbance values of BSA. SDS-PAGE was performed using Bio-Rad Mini-Protean 
Tetra Cell Electrophoresis System. MiniProtean TGX Gel (Precast) was used. After 
mixing with 2X Laemmli buffer at 1:1 volume ratio, 30 μg protein samples were 
boiled at 95°C for 5 minutes. Protein samples and protein marker was loaded to the 
wells. To compare, a COX-2 positive control; cell lysate from a macrophage cell,  
Raw 264.7 which was induced with LPS, was also loaded. Electrophoresis was 
carried out at 200V constant voltage until the dye front reaches the line near the 
bottom edge of the gel cassette. After the proteins are separated, they were 
transferred  from the gel to nitrocellulose membrane by Trans- Blot Turbo System. 
Then to check the transfer, Poncaeu staining was performed. Blocking was done for 
1 hour in 5% (w/v) non-fat dry milk in TBS-Tween, pH 7.4. After blocking 
membrane was incubated overnight with primary antibody against COX-2 (1:1000 
dilution). Then the membrane was washed 3 times with TBS Tween and incubated 
with antimouse Horseradish Peroxidase conjugated secondary antibody (1:15000 
dilution) for 2 hours. After the incubation, membrane was washed 3 times with TBS 
Tween and was incubated in PBS for 10 min. Immunodetection of membrane was 
performed using ECL-Thermo kit,  chemiluminescent signal was detected via Biorad 
Chemiluminescence imaging system. 
2.11 Determination of NFKB and Bcl2 Expression 
NFKB is a protein involved in many cellular processes including cell proliferation, 
apoptosis and tumorigenesis. Bcl2 is one of the key regulators of apoptosis which is 
over-expressed in many cancer  types (Ouyang et al, 2012). 
To determine NFKB and Bcl2 Expression, firstly RNA was isolated from cell lines 
before and after bacterial protein application. Same as COX-2 detection assay, 
CRL1790 without bacterial protein application, CRL1790 after DE8, DE365 and 
HIA applications, NCM460 without bacterial protein application, and after DE129, 
DE51 and DB7Y applications were included in this assay. Bacterial protein was 
applied onto cell lines that were seeded on 6-well plates. After 3 days of incubation, 
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RNA isolation was performed using Roche Total RNA Isolation kit and Ambion 
RNA isolation kit.  RNA concentration was determined by nanodrop measurement. 
Then according to the RNA concentration cDNA was synthesized using Fermentas 
Revertaid First Strand cDNA Synthesis Kit. Real Time PCR was performed using 
primers for Bcl2 and NFKB. PCR mix was prepared with Takara SYBR Premix Ex 
Taq II (Tli RNaseH Plus) β-actin was used as reference and for normalization. All 
samples and reference were tested in triplicate with CFX96 Real-Time PCR 
Detection System. Results were evaluated using Biorad Software.  
2.12 Statistical Analysis 
For statistical analysis, Graphpad Software was used. In MTS assay, the values were 
analysed by One way ANOVA test following Dunnett test. Using the Dunnett test, 
the mean of the absorbance values from the wells that contain different 
concentrations of bacterial proteins were compared with the mean of the negative 
control wells which contained only growth medium. Statistical analysis of real-time 
pcr results were performed by One way ANOVA following Tukey test. Using the 
Tukey test, data of the samples without bacterial protein application and with 
different bacterial protein applications were all compared to each other.  
In both tests, threshold significance level was set as 0,05. During the evaluation, p 
value lower than 0,001 ( p < 0,001) was accepted as ‘Extremely significant’ and 
defined as ‘***’. p value between 0,001 to 0,01 (p: 0,001-0,01) was accepted as 
‘Very significant’ and defined as ‘**’. p value between 0,01 to 0,05 ( p: 0,01-0,05) 
was accepted as ‘Significant’ and defined as ‘*’. p value higher than 0,05 ( p > 0,05) 
was accepted as ‘Not significant’ and defined as ‘ns’. 
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3. RESULTS 
3.1 Identification of bacterial strains  
Thirteen bacterial strains used in the present study were identified by FAME profile 
analysis and biochemical tests. To confirm the results, six bacterial strains that were 
defined as effective because of the apoptosis reduction, were also identified by 16S 
rDNA sequencing. As a result of these tests, it was determined that eleven bacteria 
belong to Enterobacter species whereas two of them were identified as Echerichia 
coli and Morganella morganii. The documents including our FAME profile analysis 
and biochemical test results were given in Appendix Part. 16S rDNA sequencing 
analysis results, which were obtained by matching in Ribosomal Database Project, 
were given below.  
In Figure 4.1, sequence matching of DB7Y was shown. As it can be observed from 
the figure, DB7Y belonged to the Enterobacter genus.  
 
Figure 4.1:  Sequence Analysis of DB7Y strain. 
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In Figure 4.2, the matching results of DE8 were given. When the similarity results 
were evaluated it was determined that DE8 was Enterobacter aerogenes. 
 
Figure 4.2: Sequence Analysis of DE8 strain. 
In Figure 4.3 , the results of DE129 was shown.  It was identified as Enterobacter 
spp. 
 
Figure 4.3: Sequence Analysis of DE129 strain. 
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Figure 4.4 included the results of DE365. It was similar to Enterobacter aerogenes 
but it could also be identified as Enterobacter spp. 
 
Figure 4.4 : Sequence Analysis of DE365 strain. 
Figure 4.5 possessed DE51 results. As it can be observed, DE51 belonged to the 
Morganella genus. It was very similar to Morganella morganii. 
 
Figure 4.5 : Sequence Analysis of  DE51. 
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In Figure 4.6 results of HIA were given. HIA belonged to the Escherichia/Shigella 
genus. It was found mostly similar to Escherichia coli. 
 
Figure 4.6: Sequence Analysis of HIA strain. 
3.2 Phylogenetic Analysis of The Effective Enterobacter Species 
Figure 5.1 demonstrated the phylogenetic analysis of Enterobacter strains. The 
nearby location of  DE365 and DE129 followed by DB7Y, indicated that they were 
familiar. DE8, which was located far from the other strains, were familiar with 
Enterobacter aerogenes C2111.  
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Figure 5.1: Phylogenetic tree of Enterobacter strains. 
3.3 MTS Results 
To determine the optimum bacterial protein concentration onto CRL1790 and 
NCM460 cell lines, MTS assay was performed. Absorbance-Concentration and Cell 
Viability-Concentration graphs were prepared. The concentration which had the 
highest cell viability was determined as optimum.  
Cell Proliferation Examination Result (1): 
When Cell viability – Concentration graphs were examined, it was observed that all 
of the bacterial proteins except for DE47 and DE12 increased cell proliferation in 
CRL1790 cell lines. 
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According to the test, the optimum concentration for 3h bacterial protein on 
CRL1790 cell line was determined as 2 μg. Graphs were given in Figure 6.1 and 
Figure 6.2. 
 
Figure 6.1: Absorbance - Concentration Graphic of CRL1790 cell line-3h. 
 
Figure 6.2 : Cell viability - Concentration Graphic of CRL1790 cell line-3h. 
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The optimum concentration for DB7Y bacterial protein on CRL1790 cell line was 
determined as 6 μg in MTS assay. Graphs were given in Figure 6.3 and Figure 6.4.  
 
Figure 6.3: Absorbance - Concentration Graphic of CRL1790 cell line -DB7Y. 
 
Figure 6.4 : Cell viability - Concentration Graphic of CRL1790 cell line -DB7Y. 
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The optimum concentration for DE8 bacterial protein on CRL1790 cell line was 
determined as 8 μg in MTS assay. Graphs were given in Figure 6.5 and Figure 6.6. 
 
Figure 6.5: Absorbance - Concentration Graphic of  CRL1790 cell line -DE8. 
 
Figure 6.6 : Cell viability - Concentration Graphic of CRL1790 cell line -DE8. 
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The optimum concentration for DE12 bacterial protein on CRL1790 cell line was 
determined as 10 μg in MTS assay. Graphs were given in Figure 6.7 and Figure 6.8. 
 
Figure 6.7: Absorbance - Concentration Graphic of CRL1790 cell line -DE12. 
 
Figure 6.8 : Cell viability - Concentration Graphic of CRL1790 cell line -DE12. 
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The optimum concentration for DE36 bacterial protein on CRL1790 cell line was 
determined as 12 μg in MTS assay. Graphs were given in Figure 6.9 and Figure 6.10. 
 
Figure 6.9: Absorbance - Concentration Graphic of CRL1790 cell line -DE36. 
 
Figure 6.10 : Cell viability - Concentration Graphic of CRL1790 cell line -DE36. 
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The optimum concentration for DE47 bacterial protein on CRL1790 cell line was 
determined as 15 μg in MTS assay. Graphs were given in Figure 6.11 and Figure 
6.12. 
 
Figure 6.11: Absorbance - Concentration Graphic of CRL1790 cell line -DE47. 
 
Figure 6.12 : Cell viability - Concentration Graphic of CRL1790 cell line -DE47. 
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The optimum concentration for DE103 bacterial protein on CRL1790 cell line was 
determined as 12 μg in MTS assay. Graphs were given in Figure 6.13 and Figure 
6.14. 
 
Figure 6.13: Absorbance - Concentration Graphic of CRL1790 cell line -DE103. 
 
Figure 6.14 : Cell viability - Concentration Graphic of CRL1790 cell line -DE103. 
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The optimum concentration for DE129 bacterial protein on CRL1790 cell line was 
determined as 12 μg in MTS assay. Graphs were given in Figure 6.15 and Figure 
6.16. 
 
Figure 6.15: Absorbance - Concentration Graphic of CRL1790 cell line -DE129. 
 
Figure 6.16 : Cell viability - Concentration Graphic of CRL1790 cell line -DE129. 
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The optimum concentration for DE256 bacterial protein on CRL1790 cell line was 
determined as 12 μg in MTS assay. Graphs were given in Figure 6.17 and Figure 
6.18. 
 
Figure 6.17: Absorbance - Concentration Graphic of CRL1790 cell line -DE256. 
 
Figure 6.18 : Cell viability - Concentration Graphic of CRL1790 cell line -DE256. 
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The optimum concentration for DE365 bacterial protein on CRL1790 cell line was 
determined as 12 μg in MTS assay. Graphs were given in Figure 6.19 and Figure 
6.20. 
 
Figure 6.19: Absorbance - Concentration Graphic of CRL1790 cell line -DE365. 
 
Figure 6.20 : Cell viability - Concentration Graphic of CRL1790 cell line -DE365. 
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The optimum concentration for huc2 bacterial protein on CRL1790 cell line was 
determined as 6 μg in MTS assay. Graphs were given in Figure 6.21 and Figure 6.22. 
 
Figure 6.21: Absorbance - Concentration Graphic of CRL1790 cell line -huc2. 
 
Figure 6.22 : Cell viability - Concentration Graphic of CRL1790 cell line -huc2. 
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The optimum concentration for HIA bacterial protein on CRL1790 cell line was 
determined as 2 μg in MTS assay. Graphs were given in Figure 6.23 and Figure 6.24. 
 
Figure 6.23: Absorbance - Concentration Graphic of CRL1790 cell line -HIA. 
 
Figure 6.24 : Cell viability - Concentration Graphic of CRL1790 cell line -HIA. 
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The optimum concentration for DE51 bacterial protein on CRL1790 cell line was 
determined as 12 μg in MTS assay. Graphs were given in Figure 6.25 and Figure 
6.26. 
 
Figure 6.25: Absorbance - Concentration Graphic of CRL1790 cell line -DE51. 
 
Figure 6.26 : Cell viability - Concentration Graphic of CRL1790 cell line -DE51. 
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The optimum concentration for 3h bacterial protein on NCM460 cell line was 
determined as 10 μg in MTS assay. Graphs were given in Figure 6.27 and Figure 
6.28. 
 
Figure 6.27: Absorbance - Concentration Graphic of NCM460 cell line -3h. 
 
Figure 6.28 : Cell viability - Concentration Graphic of NCM460 cell line -3h. 
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The optimum concentration for DB7Y bacterial protein on NCM460 cell line was 
determined as 4 μg in MTS assay. Graphs were given in Figure 6.29 and Figure 6.30. 
 
Figure 6.29: Absorbance - Concentration Graphic of NCM460 cell line -DB7Y. 
 
Figure 6.30 : Cell viability - Concentration Graphic of NCM460 cell line -DB7Y. 
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The optimum concentration for DE8 bacterial protein on NCM460 cell line was 
determined as 12 μg in MTS assay. Graphs were given in Figure 6.31 and Figure 
6.32. 
 
Figure 6.31: Absorbance - Concentration Graphic of NCM460 cell line -DE8. 
 
Figure 6.32: Cell viability - Concentration Graphic of NCM460 cell line -DE8. 
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The optimum concentration for DE12 bacterial protein on NCM460 cell line was 
determined as 8 μg in MTS assay. Graphs were given in Figure 6.33 and Figure 6.34. 
 
Figure 6.33: Absorbance - Concentration Graphic of NCM460 cell line -DE12. 
 
Figure 6.34 : Cell viability - Concentration Graphic of NCM460 cell line -DE12. 
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The optimum concentration for DE36 bacterial protein on NCM460 cell line was 
determined as 8 μg in MTS assay. Graphs were given in Figure 6.35 and Figure 6.36. 
 
Figure 6.35: Absorbance - Concentration Graphic of NCM460 cell line -DE36. 
 
Figure 6.36 : Cell viability - Concentration Graphic of NCM460 cell line -DE36. 
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The optimum concentration for DE47 bacterial protein on NCM460 cell line was 
determined as 4 μg in MTS assay. Graphs were given in Figure 6.37 and Figure 6.38. 
 
Figure 6.37: Absorbance - Concentration Graphic of NCM460 cell line -DE47. 
 
Figure 6.38 : Cell viability - Concentration Graphic of NCM460 cell line -DE47. 
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The optimum concentration for DE103 bacterial protein on NCM460 cell line was 
determined as 10 μg in MTS assay. Graphs were given in Figure 6.39 and Figure 
6.40. 
 
Figure 6.39: Absorbance - Concentration Graphic of NCM460 cell line -DE103. 
 
Figure 6.40 : Cell viability - Concentration Graphic of NCM460 cell line -DE103. 
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The optimum concentration for DE129 bacterial protein on NCM460 cell line was 
determined as 8 μg in MTS assay. Graphs were given in Figure 6.41 and Figure 6.42. 
 
Figure 6.41: Absorbance - Concentration Graphic of NCM460 cell line -DE129. 
 
Figure 6.42 : Cell viability - Concentration Graphic of NCM460 cell line -DE129. 
  
59 
 
The optimum concentration for DE256 bacterial protein on NCM460 cell line was 
determined as 10 μg in MTS assay. Graphs were given in Figure 6.43 and Figure 
6.44. 
 
Figure 6.43: Absorbance - Concentration Graphic of NCM460 cell line -DE256. 
 
Figure 6.44 : Cell viability - Concentration Graphic of NCM460 cell line -DE256. 
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The optimum concentration for DE365 bacterial protein on NCM460 cell line was 
determined as 15 μg in MTS assay. Graphs were given in Figure 6.45 and Figure 
6.46. 
 
Figure 6.45: Absorbance - Concentration Graphic of NCM460 cell line -DE365. 
 
Figure 6.46 : Cell viability - Concentration Graphic of NCM460 cell line -DE365. 
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The optimum concentration for huc2 bacterial protein on NCM460 cell line was 
determined as 10 μg in MTS assay. Graphs were given in Figure 6.47 and Figure 
6.48. 
 
Figure 6.47: Absorbance - Concentration Graphic of NCM460 cell line -huc2. 
 
Figure 6.48 : Cell viability - Concentration Graphic of NCM460 cell line -huc2. 
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The optimum concentration for HIA bacterial protein on NCM460 cell line was 
determined as 6 μg in MTS assay. Graphs were given in Figure 6.49 and Figure 6.50. 
 
Figure 6.49: Absorbance - Concentration Graphic of NCM460 cell line -HIA. 
 
Figure 6.50 : Cell viability - Concentration Graphic of NCM460 cell line -HIA. 
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The optimum concentration for DE51 bacterial protein on NCM460 cell line was 
determined as 4 μg in MTS assay. Graphs were given in Figure 6.51 and Figure 6.52. 
 
Figure 6.51: Absorbance - Concentration Graphic of NCM460 cell line -DE51. 
 
Figure 6.52 : Cell viability - Concentration Graphic of NCM460 cell line -DE51. 
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Cell Proliferation Examination Result (2): 
The samples such as DB7Y, DE129, DE47 and DE51 had the highest cell viability 
and proliferation in NCM 460 cell lines, which were near to the level of negative 
control. At optimum concentrations the cell viability % of the samples were found at 
the level of negative control.   
3.4 Apoptosis and Cell Viability Assay Results 
The presence of apoptosis was detected by annexin V in the present study. During 
the evaluation, in Flow cytometry reports, in quadrants the lower left side represents 
the viable cells which are Annexin V negative and pi negative whereas the upper left 
side represents the dead cells which are Annexin V negative but pi positive. Upper 
right side shows the late apoptotic cells or sometimes dead cells which are both 
Annexin V positive and pi positive. Finally the lower right side shows the early 
apoptotic cells that are Annexin V positive but pi negative. The results of the 
apoptosis test were summarized in Table 2.1. Flow cytometry reports of the samples 
that decreased the apoptosis were given below. Reports of the other samples were 
shown in Appendix part.  
From the Figure 7.1, Annexin in CRL1790 before application was determined as 
10.55. In Figures 7.2, 7.3 and 7.4, it was shown that Annexin measurement was, 
7.12, 4.37 and 6.56 after DE365, DE8 and HIA application, respectively . 
Figure 7.1: Detection of Apoptosis by Annexin in CRL1790 before bacterial               
protein application. 
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Figure 7.2:  Detection of Apoptosis by Annexin in CRL1790 after DE365 protein 
 application. 
Figure 7.3: Detection of Apoptosis by Annexin in CRL1790 after DE8 protein 
 application. 
Figure 7.4: Detection of Apoptosis by Annexin in CRL1790 after HIA protein 
 application. 
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In Figure 7.5 it was shown that Annexin in NCM460 before application was 7.40. 
From the other Figures 7.6, 7.7 and 7.8, Annexin level in NCM460 was determined 
as  0.32, 6.91 and 5.13 after DB7Y, DE129 and DE51 application, respectively.  
Figure 7.5 :  Detection of Apoptosis by Annexin in NCM460 before bacterial 
    protein application. 
 
Figure 7.6 : Detection of Apoptosis by Annexin in NCM460 after DB7Y protein 
application. 
Figure 7.7 : Detection of Apoptosis by Annexin in NCM460 after DE129 protein 
application. 
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Figure 7.8: Detection of Apoptosis by Annexin in NCM460  after DE51 protein 
application. 
Table 2.1  : Apoptosis assay results. 
 
CRL1790 NCM460 
 
Annexin Pi Annexin Pi 
Neg. 10,55 1,8 7,4 4,74 
3h 10,84 4,37 7,22 4,97 
HIA 6,56 3,55 9,62 8,76 
Huc2 11,16 3,51 11,19 8,45 
DE129 21,53 9,45 6,91 8,46 
DE51 34,48 6,97 5,13 3,81 
DE365 7,12 3,98 14,74 7,9 
DE8 4,37 3,69 7,68 7,08 
DE12 14,88 6,26 11,94 10,48 
DE47 10,61 6,59 8,74 9,12 
DE36 8,27 4,54 9,33 8,43 
DE256 11,8 3,57 7,65 6,88 
DE103 14,8 6,03 8,57 5,32 
DB7Y 14,23 5,74 0,32 1,92 
In this assay, as shown in Table 2.1, annexin values of the cell lines without 
application of bacterial protein were determined as 10,55 and 7,4 for CRL1790 and 
NCM460 cell lines, respectively. 3 bacterial strains signed as HIA, DE365 and DE8 
decreased the annexin level on CRL1790 cell lines whereas 3 bacterial strains 
DE129, DE51 and DB7Y decreased annexin on NCM460 cell lines. Even, DB7Y 
decreased annexin level to 0,32 from 7,4.  Pi levels were also low for those samples. 
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3.5 CD24 Detection Results 
CD24 values in this study were measured by flow cytometry. Isotype values were the 
background signal. In order to calculate the CD24 level, Isotype values for all 
samples were extracted from the CD24 values. In Table 3.1, all the results of the 
CD24 Detection assay in the present study were summarized. Flow cytometry reports 
including the results of  the bacterial strains that decreased the apoptosis in the 
previous test were shown below. The reports of the other bacterial strains tested in 
the study were given in Appendix part. 
As it was shown in Figure 8.1, CD24 was measured as 31.8 in CRL1790 before 
bacterial protein application. Isotype measurement of the same sample (Figure 8.2) 
was measured as 23.43. 
Figure 8.1: CD24 Detection in CRL1790 before bacterial protein application. 
Figure 8.2: Isotype measurement in CRL1790 before bacterial protein application. 
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From the Figure 8.3 it can be observed that, CD24 was measured as 75.16 in 
CRL1790 after DE365 protein application. Isotype  measurement of the sample, was 
determined as 16.09  (Figure 8.4). 
Figure 8.3: CD24 Detection in CRL1790 after DE365 protein application. 
Figure 8.4:  Isotype measurement in CRL1790 after DE365 protein application. 
According to the Figures 8.5 and 8.6, CD24 was determined as 66,67 and isotype as 
37,62 in CRL1790 after DE8 protein application.  
Figure 8.5:  CD24 Detection in CRL1790 after DE8 protein application. 
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Figure 8.6:  Isotype measurement in CRL1790 after DE8 protein application. 
CD24 was measured as 45,67 (Figure 8.7) and isotype as 27,17 (Figure 8.8) in 
CRL1790 after HIA protein application.  
Figure 8.7:  CD24 Detection in CRL1790 after HIA protein application. 
Figure 8.8:  Isotype measurement in CRL1790 after HIA protein application. 
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Table 3.1: CD24 detection results. 
 
CRL1790 NCM460 
 
CD24 Calculation ISOTYPE CD24 Calculation ISOTYPE 
Neg. 31,88 8,45 23,43 31,57 26,71 4,86 
3h 55,91 28,09 27,82 16,9 12,12 4,78 
HIA 45,67 18,5 27,17 24,49 15,18 9,31 
Huc2 69,9 30,59 39,31 26,05 20,17 5,88 
DE129 74,61 44,56 30,05 15,6 13,2 2,4 
DE51 61,38 23,07 38,31 23,23 17,26 5,97 
DE365 75,16 59,07 16,09 20,68 14,75 5,93 
DE8 66,67 29,05 37,62 26,67 20,97 5,7 
DE12 54,65 12,91 41,74 22,84 16,16 6,68 
DE47 88,62 25,73 62,89 29,11 24,23 4,88 
DE36 50,97 22,25 28,72 9,02 3,05 5,97 
DE256 52,99 21,91 31,08 23,73 19,02 4,71 
DE103 62,01 25,35 36,66 23,68 17,46 6,22 
DB7Y 56,03 20,09 35,94 27,99 22,76 5,23 
 
According to Table 3.1, it was determined that all of the bacterial strains tested in the 
present study increased CD24 level on CRL1790 compared with those before 
application (8.45) The highest level was observed after DE365 application. (59,07) 
CD24 level was determined as 26,71 on NCM460 cell line before application. But no 
increase was observed on NCM460 after treatment.  
A combination of CD24 and apoptosis detection assay results were given on Table 
4.1. 
  
72 
 
Table 4.1: Comparison of the results. 
 
CRL1790 NCM460 
Application CD24 DETECTION APOPTOSIS CD24 DETECTION APOPTOSIS 
 
CD24 
 
ISOTYPE ANNEXIN PI CD24 
 
ISOTYPE ANNEXIN PI 
CRL1790 31,88 
 
23,43 10,55 1,8 
     NCM460 
     
31,57 
 
4,86 7,4 4,74 
Calculation 
 
8,45 
    
26,71 
   3h 55,91 28,09 27,82 10,84 4,37 16,9 12,12 4,78 7,22 4,97 
HIA 45,67 18,5 27,17 6,56 3,55 24,49 15,18 9,31 9,62 8,76 
Huc2 69,9 30,59 39,31 11,16 3,51 26,05 20,17 5,88 11,19 8,45 
DE129 74,61 44,56 30,05 21,53 9,45 15,6 13,2 2,4 6,91 8,46 
DE51 61,38 23,07 38,31 34,48 6,97 23,23 17,26 5,97 5,13 3,81 
DE365 75,16 59,07 16,09 7,12 3,98 20,68 14,75 5,93 14,74 7,9 
DE8 66,67 29,05 37,62 4,37 3,69 26,67 20,97 5,7 7,68 7,08 
DE12 54,65 12,91 41,74 14,88 6,26 22,84 16,16 6,68 11,94 10,48 
DE47 88,62 25,73 62,89 10,61 6,59 29,11 24,23 4,88 8,74 9,12 
DE36 50,97 22,25 28,72 8,27 4,54 9,02 3,05 5,97 9,33 8,43 
DE256 52,99 21,91 31,08 11,8 3,57 23,73 19,02 4,71 7,65 6,88 
DE103 62,01 25,35 36,66 14,8 6,03 23,68 17,46 6,22 8,57 5,32 
DB7Y 56,03 20,09 35,94 14,23 5,74 27,99 22,76 5,23 0,32 1,92 
The data  showed that in addition to the apoptosis reduction, 3 bacterial strains coded 
as HIA, DE365 and DE8 increased the CD24 level on CRL1790 cell line. Whereas 
another group of  bacterial strains including DB7Y, DE129 and DE51 decreased 
apoptosis on NCM 460 cell line. The lowest annexin value was observed after DB7Y 
application (0,32). 
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 3.6 COX-2 Detection Results 
Presence of  COX2  was determined by Western Blotting technique. The 6 samples 
including DB7Y, DE365, DE129, DE8, DE51 and HIA that decreased the apoptosis 
after annexin test, were included in this assay. Cell lysates were prepared from 
NCM460 and CRL1790  before and after bacterial protein application. As positive 
control , Raw 264.7, a cell lysate from a macrophage cell that was induced with LPS, 
was used. Positive control band was shown in Figure 9.1a. In Figure 9.1b, the 
transferred proteins to the nitrocellulose membrane after Poncaeu staining can be 
observed. 
As a result, all of  the samples tested were determined as COX-2 negative. The 
experiment was performed twice and same result was obtained. 
 
a      b 
Figure 9.1: COX2 Determination by Western Blotting 
   a) After incubation with COX2 antibody  
   b) After Poncaeu staining 
3.7 NFKB and Bcl2 Expression Assay Results 
Similar to COX-2 detection, the 6 samples including DB7Y, DE365, DE129, DE8, 
DE51 and HIA that decreased the apoptosis after annexin test, were included in this 
assay. Real-Time PCR Results were given below. 
In Figure 10.1 Relative Normalized Expression of NFKB on NCM 460 cell lines 
with and without bacterial protein was shown. The blue colored sample which was 
signed as NCM 460 represented the cell line without application.  It was observed 
from the graph that bacterial protein application increased NFKB expression in 
NCM460 cell lines. The highest expression of  NFKB  belonged to DB7Y (yellow 
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color) followed by DE129  (white color). The least expression belonged to DE51 on 
NCM460 cell lines. 
 
Figure 10.1: Relative Normalized Expression of NFKB on NCM460 cell line. 
As shown in Figure 10.2, all bacterial treatment increased the expression of  Bcl2. 
The highest expression was observed after DB7Y treatment (light blue) followed by 
DE51 (dark blue) and DE129 (pink color) compared with NCM460 before treatment 
(green). 
 
Figure 10.2: Relative Normalized Expression of Bcl2 on NCM 460 cell line. 
In Figure 10.3, Relative Normalized Expression of  NFKB on CRL1790 cell lines 
before and after bacterial treatment was shown. The pink colored column represented 
the result of the CRL1790 cell line before bacterial protein application. As it was 
observed from the graph, the highest expression belonged to DE365 (yellow) 
followed by DE8 (blue). There was no increase in NFKB expression after HIA 
(white) treatment. 
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Figure 10.3: Relative Normalized Expression of NFKB on CRL1790 cell line. 
In Figure 10.4, Relative Normalized Expression of  Bcl2 on CRL1790 cell lines with 
and without bacterial protein application was shown. According to the graph, only 
DE365 (pink) treatment increased the Bcl2 expression compared with CRL1790 
(green) before treatment. No increase was observed in Bcl2 expression after DE8 
(light blue) and HIA (dark blue) treatment. 
 
Figure 10.4: Relative Normalized Expression of Bcl2 on CRL1790 cell line. 
Statistical Analysis of the NFKB and Bcl2 expression was performed by One way 
ANOVA following Tukey test in Graphpad Software. Figure 11.1 showed NFKB 
expression on NCM460 cell line.  According to the graph, all bacterial treatment 
increased the expression. Figure 11.2 showed Bcl2 expression on NCM460 cell line. 
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Figure 11.1: NFKB Expression on NCM460 cell line after statistical analysis. 
 
Figure 11.2 : Bcl2 Expression on NCM460 cell line after statistical analysis. 
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Figure 11.3 showed NFKB expression on CRL1790 cell line. Figure 11.4 showed 
Bcl2 expression on CRL1790 cell line.  
 
Figure 11.3: NFKB Expression on CRL1790 cell line after statistical analysis. 
 
Figure 11.4 : Bcl2 Expression on CRL1790 cell line after statistical analysis. 
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4. DISCUSSION AND CONCLUSIONS 
Cancer is a disease characterized by uncontrolled growth and spread of abnormal 
cells. Unless the spread is controlled, it can lead to death.  If  it is detected at an early 
stage, it is more treatable. Surgery, radiation, chemotherapy, hormones and 
immunotherapy are the approaches to make the treatment (American Cancer Society, 
2011-b). 
Colon cancer is the third most common cancer globally. Worldwide 1.2 million cases 
occurred in 2008 (American Cancer Society, 2011-b). Different factors including, 
age, diet, genetic diseases, physical inactivity, being overweight or obese are 
effective in colon carcinogenesis. People, who have had colorectal cancer or have 
one or more polyps, are in risk group. One of the most important factor that causes 
colon cancer is the inflammation. People who have chronic inflammatory bowel 
disease are in risk for colorectal cancer. Sporadic colon cancer and colitis associated 
colon cancer follow different pathways in tumorigenesis. Apoptotic pathways are 
also effective in colon carcinogenesis (American Cancer Society, 2011-a; Rupnarain 
et al, 2004). 
Many studies were performed to determine the interaction between bacteria and 
colon cancer. The gram negative, rod shaped bacteria, Enterobacter can be observed 
in various areas including freshwater, sewage, soil, vegetables, human and animal 
intestines and the hospital environment. They are nosocomial pathogens that exist in 
many infections such as urinary tract infections, bacteremia, ventilator-associated 
pneumonia and meningitis and brain abcess. Infections are mostly caused by 
Enterobacter aerogenes and Enterobacter cloacae strains. Antibiotic resistance can 
be observed among Enterobacter strains against ampicillins, cephalosporins 
(Grimont and Grimont, 2006; Breathnach et al, 2006). Up to now, no study was 
performed to demonstrate a possible relationship between  Enterobacter spp. and 
colon cancer. Therefore, it was aimed to investigate the effects of Enterobacter 
strains on colon cancer in the present study. 
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In our study, the tumorigenic potential of 11 bacterial strains in the genera of 
Enterobacter, 1 Esherichia coli and 1 Morganella morganii strain were investigated. 
Our approach first of all was to isolate the bacterial proteins and apply them onto 
healthy colonic epithelial cell lines. After incubation, cell viability and proliferation, 
presence of apoptosis, and level of tumor markers such as CD24, COX-2, NFKB and 
Bcl2 were screened. 
Presence of apoptosis before and after bacterial protein application was determined 
by Annexin V. Before application of bacterial protein, Annexin V values were 
determined as 10,55 and 7,4 for CRL1790 and NCM460 cell lines, respectively. The 
result of the experiment showed that six bacterial strains including HIA, DE365, 
DE8, DE129, DE51 and DB7Y decreased annexin on either CRL1790 or NCM460 . 
CD24 is a cell surface protein, which is expressed especially on premature 
lymphocytes, epithelial cells, and neural cells. It is a small, heavily glycosylated 
protein core that consists of 27 amino acids. It is effective in cell selection and 
maturation during hematopoiesis. It is expressed during the embryonic period on 
developing neural cells and pancreatic cells. CD24 is overexpressed in various 
malignant tissues, including B-cell lymphomas, gliomas, and small cell lung, 
hepatocellular, uterine, ovarian, breast, prostate and pancreatic carcinomas. Because 
it is the ligand of P-selectin and the adhesion receptor found in activated endothelial 
cells and platelets, CD24 is considered to be associated with tumor metastasis (Sagiv 
et al, 2006; Lim, 2005; Choi et al, 2006). Studies show that CD24 is overexpressed in 
the colonic mucosa at an early stage of carcinogenesis and overexpression of CD24 
can be a specific marker of disease progression from the premalignant tumor phase to 
the development of carcinoma (Sagiv et al, 2006; Choi et al, 2006). 
In our study, expression level of CD24 on CRL1790 and NCM460 before and after 
bacterial protein application was analysed. The results showed that there was no 
increase in CD24 level in NCM460 cell line. In fact, there was a decrease in most of 
the samples. However, CD24 level was not so affected after application of DE47 and 
DB7Y proteins on NCM460 cell line. Whereas in CRL1790, after treatment of the 
three strains coded as DE365, DE8 and HIA, an increase in CD24 level was observed 
compared with those before treatment. This difference may occur as a result of the 
differences between cell lines. CRL1790 is a colonic epithelial cell line driven from a 
21 week gestation female fetus, whereas NCM 460 cell line is driven from normal 
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colonic mucosa of 68 year old male. (ATCC and incell product sheet) Pathogenic 
effects on different cell lines may be related with different metabolites, which can be 
produced by various microorganisms, and pathogenic abilities can differ among 
bacterial strains. As a result of this, they can follow different pathways to cause 
diseases. As it was explained in the introduction part, colon has different parts called 
as ascending colon, transverse colon, descending colon and sigmoid colon. In 
different parts of the colon, different bacterial strains can colonize. The prevalence of 
bacteria in different parts of the gastrointestinal tract depends on several factors such 
as pH, peristalsis, redox potential, bacterial adhesion, bacterial cooperation, mucin 
secretion, nutrient availability, diet and bacterial antagonism. The stomach and the 
upper two-thirds of the small intestine (duodenum and jejunum) contain low numbers 
of microorganisms because of the low pH and the swift peristalsis through the 
stomach and the small bowel. In the distal part of the small intestine, which is called 
as the ileum, similar to the colon, there is high bacterial population and diverse 
microflora because of the decreased peristalsis, acidity and lower oxidation-reduction 
potential. Slow intestinal motility, and very low oxidation-reduction potential makes 
the colon the primary site of microbial colonization in humans (Hao and Lee, 2004). 
In a study that was performed to determine the bacterial populations in the distal 
small bowel and colon, it was found that Bifidobacterial numbers were significantly 
higher in the large bowel than in the terminal ileum whereas lactobacilli were more 
prominent in the distal large intestine. Eubacterium rectale and Faecalibacterium 
prausnitzii were dominant in the ascending and descending colon (Ahmed et al, 
2007). Because the bacterial strains can exist in different parts of the colon, if the cell 
lines were not driven from the same part of the colon, the effect of bacterial proteins 
on those cell lines may also differ. Those properties may lead to the result, as a group 
of bacteria were found effective against NCM 460 cell line whereas another group 
was effective against CRL1790 in our study. Since all bacteria may differ based on 
their pathogenic abilities, some bacterial strains increased CD24 level and decreased 
apoptosis at the same time whereas in some only apoptosis was reduced without an 
alteration in CD24 level. 
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In our study, it was demonstrated that apoptosis decreased after bacterial protein 
application when compared with those before application. As a next step, to clarify 
the apoptosis reduction mechanism of those 6 effective bacterial strains, NFKB and 
Bcl2 expression of the cell lines before and after bacterial protein application were 
determined. When NFKB expression was tested before and after bacterial protein 
application, it was determined that the bacterial protein signed as DB7Y, increased 
NFKB expression on NCM460 cell line when compared with those before 
application. After statistical analysis, the increase that was observed in DB7Y was 
found as extremely significant ( p < 0,001). DE129 also significantly increased 
NFKB on NCM460 ( p: 0,01-0,05 ). In regards to the CRL1790 cell line, the strain 
coded as DE365 increased NFKB when compared with the one without application 
and similar to the DB7Y results, the increase in DE365 was found as extremely 
significant (p < 0,001). Also another Enterobacter strain, signed as DE8, 
significantly increased NFKB expression ( p: 0,01-0,05 ). But the increase in DE365 
was found higher than that of the increase in DE8.  
NFKB (The nuclear factor KB) is a transcription factor, which is involved, in many 
biological pathways. Immune mediating genes, inflammatory genes, antiapoptotic 
genes, cell proliferation regulation genes are targets of NFKB. NFKB consists of a 
family of Rel-domain-containing proteins, which includes Rel A (also called p65), 
Rel B, c-Rel, p50 (also called NFKB1) and p52 (also called NFKB2). NFKB exists 
in the cytoplasm in an inactive state, which is inhibited by NFKB. In the presence of 
extracellular stimuli, such as cytokines, phosphorylation, ubiquitination, and 
proteolytic degradation occurs by either canonical IKB kinase complex-dependent 
pathway or noncanonical NFKB inducing kinase pathway. Phosphorylation by casein 
kinase 2 may also lead to IKB degradation. NFKB is released after IKB degradation, 
and then it translocate to the nucleus. NFKB binds to the promoter regions of its 
target genes, which control immune system, growth and inflammation. 
Phosphorylation of NFKB is also required for activation (Lu et al, 2006; Shishodia, 
2004). 
NFKB is actually required for the normal functioning of immune system. Regulation 
of the expression of cytokine genes, functioning in hematopoiesis, antigen 
presentation, B cell development and proliferation, T cell development and 
proliferation are the beneficial activities of NFKB. In normal cells NFKB activation 
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occurs as a result of a stimuli, but in tumor cells different molecular alterations lead 
to impaired regulation of NFKB activation, which results in constitutively activation. 
Therefore, deregulated expression is observed in genes, which are under NFKB 
control. Genes that are involved in apoptosis regulation, cell cycle control, adhesion 
and migration are affected. Constitutively active NFKB has been detected in many 
tumors such as multiple myeloma, acute myelogenous leukemia, acute lymphocyte 
leukemia, chronic myelogenous leukemia, prostate and breast cancers. It was shown 
that suppression of NFKB in these tumors, inhibit proliferation, cause cell cycle 
arrest and lead to apoptosis (Dolcet et al, 2005; Shishodia, 2004). 
It was determined that NFKB is related to carcinogenesis by activating tumor-
promoting cytokines or by activating NFKB signaling in premalignant cells  and 
immune/ inflammatory cells. In studies, it was demonstrated that, NFKB was 
detected both in colorectal and colitis-associated tumors. The activation mechanism 
of NFKB in tumorigenesis can be summarized as increasing cell proliferation and 
angiogenesis, inhibiting cell death, promoting cell invasion and metastasis (Terzic et 
al, 2010). In epithelial cells, NFKB activation is involved mainly in the promotion 
and progression steps of colitis associated colorectal cancer (Wang et al, 2009). 
Members of NFKB family can be oncogenic. It was determined that c-Rel transforms 
cell in culture. c-Rel is activated in an avian B cell lymphoma and in human it is 
observed in Hodgkin’s lymphoma. Some oncogenes are shown to activate NFKB. 
Oncogenic Ras, that is active in many tumor types such as prostate and colon cancer, 
has been shown to activate NFKB. Cytokines including IL-1, TNF and IL-6 which 
can be growth factors for tumor cells, are regulated by NFKB . EGF, a growth factor 
in tumors activates NFKB. Cytokines are either regulated by NFKB or mediate 
proliferation by NFKB activation. Cyclin D1, which is a cell cycle protein required 
for entry of cells from G1 to S phase is also regulated by NFKB. Tumor invasion and 
metastasis processes, which are regulated by gene products such as matrix 
metalloproteinase, urinary plasminogen activator and interleukin-8, are regulated by 
NFKB (Shishodia, 2004). 
In a study performed, 28 resected colorectal carcinomas and colonic mucosa from 
healthy portions were tested for NFKB activation and in tumors much greater 
activation was observed when compared with those in normal colonic mucosa. 
Researchers also indicate a relationship between NFKB activation and cell 
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proliferation (Kojima et al, 2004).  Angiogenesis defined, as blood vessel formation 
is an important process for solid tumors to grow. Production of angiogenic factors 
including TNF, VEGF, MCP-1 and IL-8 is regulated by NFKB. In colorectal cancer, 
it was determined that NFKB and VEGF was significantly overexpressed and 
associated with the increased microvessel density. It was suggested that increased 
expression of NFKB in colorectal cancer, contributes to tumor angiogenesis  
(Shishodia, 2004).  
NFKB is required for neutrophil chemotaxis, it regulates inflammatory cell apoptosis 
and phagocytosis which shows the function of NFKB in chronic inflammation. In 
connection to carcinogenesis, NFKB suppresses apoptosis (Lu et al, 2006). The 
oncogenic role of NFKB, related with its antiapoptotic function, is especially through 
Bcl2, Bcl-XL and cFLIP  activation (Karin, 2009, Terzic et al, 2010). NFKB up 
regulates the expression of FLICE-like inhibitory protein (FLIP). FLIP is a homolog 
of caspase 8 but lacks protease activity. It competes with caspase 8 for the binding to 
the Death- Inducing Signaling Complex. High levels of FLIP, prevents binding of 
caspase 8. FLIP upregulation is observed in many tumors. The expression of 
Inhibitors of Apoptosis (IAPs), members of the Bcl2 family, is induced by NFKB. 
IAPs suppress apoptosis by inhibiting caspases (caspases -3, -6, -7 and -9) PTEN, a 
tumor suppressor gene, is a negative regulator in P13K/Akt pathway. Studies show 
that NFKB decreases PTEN, decreased PTEN increases Akt activity and suppresses 
apoptosis (Dolcet et al, 2005). 
Expression of adhesion molecules such as ICAM -1, VCAM-1 and ELAM-1  which 
are active in metastasis are regulated by NFKB. Inducible Nitric Oxide Synthase 
(INOS), again related with tumor metastasis, is also regulated by NFKB (Shishodia, 
2004). 
COX-2 is accepted as another marker, which is up regulated during colon cancer. 
(COX) Cyclooxygenase enzyme is required in prostaglandin biosynthesis. COX-2 
was reported to modulate cell proliferation and apoptosis in many colorectal, breast, 
prostate cancers and also in hematological malignancies (Dixon et al, 2013; 
Sobolewski et al, 2010). The cell lines; CRL1790, and NCM460, that were used in 
this study were found COX-2 negative before and after bacterial protein application. 
This result indicates that the bacteria strains that we tested, used different pathways. 
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Bcl2 was the first protein that was identified in this family and derived its name from 
B cell lymphoma. Bcl2 members, which are located on the outer mitochondrial 
membrane, are functional in membrane permeability either by forming ion channels 
or creating pores. Bcl2 family is divided into 3 groups based on Bcl2 homology 
domains and their function. Antiapoptotic proteins such as; Bcl-2, Bcl-XL, Bcl-W, 
A1/Bfl-1, Mcl-1 and Bcl-B/Bcl2L10 contain all four BH domains, is the first group. 
Second group; BH-3 only proteins, which is restricted to the BH3 domain, are 
initiators of apoptosis. This group includes; Bid, Bim, Puma, Noxa, Bad, Bmf, Hrk 
and Bik. Third group, which contains all four BH domains, is also proapoptotic. 
Examples can be given as; Bax, Bak and Bok/Mtd (Wong, 2011 ; Ouyang et al, 
2012). 
Bcl2 has no oncogenic potential as Myc or Ras, however it is oncogenic by enabling 
the cell survival in inappropriate conditions. Bcl2 performs its antiapoptotic 
functions based on the mitochondria. It could suppress the production of reactive 
oxygen species by the mitochondrion. It was also reported that antiapoptotic 
mechanism of Bcl2 is suppression of the release of cytochrome c and preventing 
caspase activation (Cotter, 2009). 
Bcl2 was determined as an important factor in the development of B cell lymphomas. 
Increased Bcl2 expression was observed in many tumors such as lung cancers, renal, 
stomach and brain cancers and non-Hodgkin’s lymphomas (Cotter, 2009). Bcl2 is 
also overexpressed in colorectal adenomas and carcinomas (Rupnarain et al, 2004; 
Sinicrope et al, 1995). In colon cancer, a gradient increase was demonstrated in Bcl2, 
during the tumor progression from adenoma to carcinoma. Expression increased in 
early stages but decreased in late stages of colon cancer (Huerta et al, 2006). 
In the present study, two bacterial strains coded as DB7Y and DE51 increased 
expression of Bcl2 in NCM 460 cell line when compared with those before 
application. The increase of Bcl2 expression in DE129 was lower than that of the 
increase in DB7Y and DE51. These data confirmed Annexin V assay results on 
Table 2.1. DE365 application, extremely increased the expression of Bcl2 in 
CRL1790 cell line  (p < 0,001) . Bcl2 expression was not affected in CRL1790 cell 
lines after DE8 and HIA application.  
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Among thirteen bacterial strains that were tested in this study, six of them were 
defined as effective either on CRL1790 or NCM460 cell line. All effective strains 
increased the cell viability and proliferation at their optimum concentrations and 
decreased apoptosis. Also, they were determined as COX-2 negative. By molecular 
techniques based on 16S rDNA sequences, fatty acid compositions and metabolic 
activities, HIA and DE51 were identified as Escherichia coli and Morganella 
morganii respectively. It was found that the remaining four bacterial strains belonged 
to the Enterobacter spp. including DB7Y, DE129 and DE365 decreased apoptosis by 
increasing NFKB and Bcl2 expression. DE365 also increased CD24 level in 
CRL1790. DE8, which was identified as Enterobacter aerogenes, increased CD24 
level as well as NFKB expression on CRL1790. However, it did not affect Bcl2 
expression. In addition to the increase in NFKB expression, these results indicate that 
DE8 may follow another pathway for  apoptosis reduction. This suggestion was also 
supported by the phylogenetic tree of the effective Enterobacter strains. When the 
effective Enterobacter strains were examined in a phylogenetic tree, it was observed 
that DE8 was located far from the others. 
Apoptosis inhibition can be observed in many bacterial strains. It is an important 
pathogenicity mechanism which enables the bacteria to replicate inside host cells. 
Some bacteria induce apoptosis but in that case they target immune cells like 
macrophages and neutrophils because otherwise these cells will kill them. Bacteria 
develop different strategies to inhibit apoptosis (Faherty and Maurelli, 2008). 
It was determined that Chlamydia trachomatis, which is an obligate intracellular 
bacteria that causes urogenital and ocular infections, inhibits Bax and Bak proteins 
and prevents them from permeabilizing the mitochondrial membrane. In Chlamydia 
infected cells, cytochrome c release and caspase activation are inhibited. It was also 
determined that Chlamydia upregulates the inhibitor of apoptosis proteins (IAPs) 
when an inducer like tumor necrosis factor α (TNF-α) was used. IAPs are apoptosis 
regulators, which function at the level of caspases (Zhong et al, 2006; Rajalingam et 
al, 2006; Faherty and Maurelli, 2008). 
By using the outer membrane porin protein PorB, Neisseria meningitidis, which is a 
gram-negative bacterium that causes bacterial meningitis and sepsis, stabilize the 
mitochondria and inhibits cytochrome c release. PorB also diminished DNA 
breakdown. As a result of immunoprecipitation experiments, researchers suggested 
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that Por B interacts with the mitochondrial porin VDAC (voltage dependent anion 
channel), which is a part of the permeability transition pore (PT) (Massari et al, 
2000; Massari et al, 2003; Faherty and Maurelli, 2008). 
Salmonella enterica serovar typhimurium is a common food-bourne pathogen, 
causes gastroenteritis. By activating the PI3K/Akt pathway which prevents 
cytochrome c release and thus inhibits the activation of caspases Salmonella enterica 
serovar typhimurium inhibits apoptosis (Knodler et al, 2005; Faherty and Maurelli, 
2008). 
 Anaplasma phagocytophilum, is an obligate intracellular bacterium that causes 
human granulocytic anaplasmosis, prevents apoptosis in neutrophils. It was 
demonstrated that Anaplasma infection upregulates antiapoptosis genes that control 
several pathways such as; p38MAPK, ERK, P13K and NFKB.  Reduction was also 
observed in caspase 3 and caspase 8 activities (Choi et al, 2005; Lee and Goodman, 
2006; Faherty and Maurelli, 2008). 
Ehrlichia chaffeensis , is a gram negative, obligate intracellular bacterium, causes 
human monocytic ehrlichiosis, inhibits apoptosis in the human monocyte cell line 
THP1 by NFKB upregulation. Bcl2 is also induced during infection (Zhang et al, 
2004;  Faherty and Maurelli, 2008). 
Another gram negative, obligate intracellular pathogen Rickettsia rickettsii, the agent 
of Rocky Mountain spotted fever, targets the vascular endothelium, prevents 
apoptosis in endothelial cells by NFKB pathway not only by upregulating the 
prosurvival proteins and downregulating the proapoptotic proteins, but also by 
inhibiting cytochrome c release and preventing activation of apical caspases -8, -9 
and effector caspase -3 (Joshi et al, 2003; Joshi et al, 2004; Faherty and Maurelli, 
2008). 
Wolbachia, is a gram negative endosymbiotic bacteria of filarial nematode parasites, 
belonged to the Anaplasmataceae family. It is important during parasitic infections 
in humans. It was found that surface protein of Wolbachia inhibits apoptosis in 
human neutrophils by preventing caspase 3 activation (Bazzocchi et al, 2007; 
Faherty and Maurelli, 2008). 
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Bartonella henselae, a slow growing, fastidious, facultative intracellular bacterium 
which causes cat scratch disease, vasculoproliferative disorders, bacillary 
angiomatosis and peliosis, inhibits apoptosis by activating NFKB, increasing 
expression of cIAP-1 and cIAP-2 and preventing caspase 3 activation (Kempf et al, 
2005; Faherty and Maurelli, 2008). 
Shigella, a gram negative pathogen that causes bacillary dysentery, can invade a 
variety of host cells such as, macrophages, dendritic cells and epithelial cells. It was 
demonstrated that, Shigella flexneri inhibits apoptosis in epithelial cells but causes 
cell death in macrophages. Apoptosis inhibition mechanism is preventing caspase 3 
activation (Suzuki et al, 2005; Clark and Maurelli, 2007; Faherty and Maurelli, 
2008). 
Toxoplasma gondii, is an intracellular parasite. It also prevents apoptosis by 
inhibition of cytochrome c induced caspase activation. (Keller et al, 2006, Faherty 
and Maurelli, 2008). 
Legionella pneumophila causes a life-threatening pneumonia called as Legionnaires 
disease, inhibits apoptosis through NFKB activation  (Abu-Zant et al, 2005; Abu-
Zant et al , 2007; Faherty and Maurelli, 2008). 
Helicobacter pylori, a gram-negative bacterium, causes gastritis and peptic ulcer. 
Studies also showed its association with gastric cancer and mucosa-associated 
lymphoid tissue (MALT) lymphoma. It inhibits apoptosis by NFKB activation 
(Yanai et al, 2003). 
As it was summarized above, many bacteria can reduce apoptosis. Our study was the 
first to demonstrate apoptosis can be inhibited by Enterobacter strains. Why is 
apoptosis inhibition so important? Apoptosis is a complex process that contains 
many pathways, at any point along these pathways defects can occur which lead to 
malignant transformation of the affected cells, tumor metastasis and resistance to 
anticancer drugs. In the previous studies, it was reported that the proto-oncogene 
Bcl-2, which inhibits apoptosis encourages tumor progression, the retinoblastoma 
protein that regulates cell cycle progression, bax, bcl- XL, mcI-I, Fas receptor and 
Fas-ligand which regulate apoptosis, contribute to tumor progression. In addition to 
the genetic changes, a few studies showed that reduction of apoptosis is important for 
carcinogenesis (Wong, 2011; Rupnarain et al, 2004). Wright, 1994 tested, 10 known 
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or suspected tumor promoters and it was found that all of them inhibited DNA 
fragmentation and cell death of 7 different cell lines. In another study, it is shown 
that Helicobacter pylori and Bartonella henselae  inhibit apoptosis and at the same 
time causes gastric carcinoma and bacillary angiomatosis, respectively (Faherty and 
Maurelli, 2008). Similarly some data in the previous works demonstrated that 
Chlamydia inhibits apoptosis, Chlamydia pneumoniae was found to be related with 
lung cancer (Mager, 2006; Zhong et al, 2006; Rajalingam et al, 2006).  
In conclusion, the present study indicates that Enterobacter strains might promote 
colon cancer. This is the first study showing that Enterobacter spp. may be clinically 
important factor for colon cancer initiation and progression. Studies can be extended 
on animal models in order to develop new strategies for treatment. 
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APPENDIX A : Detection of Apoptosis by Annexin in NCM460 
 
Figure A.1 :  Detection of Apoptosis by Annexin in NCM460 (negative-cell without 
antibody). 
 
Figure A.2 : Detection of Apoptosis by Annexin in NCM460 (only annexin). 
 
Figure A.3 : Detection of Apoptosis by Annexin in NCM460 (only pi). 
 
Figure A.4 : Detection of Apoptosis by Annexin in NCM460 (cell before bacterial 
protein application). 
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Figure A.5 : Detection of Apoptosis by Annexin in NCM460  (after 3h protein 
   application). 
 
Figure A.6 : Detection of Apoptosis by Annexin in NCM460  (after HIA protein 
 application). 
 
Figure A.7 : Detection of Apoptosis by Annexin in NCM460  (after huc2 protein 
 application). 
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Figure A.8 : Detection of Apoptosis by Annexin in NCM460  (after DE47 protein 
application). 
 
Figure A.9 : Detection of Apoptosis by Annexin in NCM460  (after DE256 protein 
application). 
 
Figure A.10 : Detection of Apoptosis by Annexin in NCM460  (after DE365 protein 
application). 
 
Figure A.11 : Detection of Apoptosis by Annexin in NCM460  (after DE36 protein 
 application).  
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Figure A.12 : Detection of Apoptosis by Annexin in NCM460  (after DE12 protein 
 application). 
 
Figure A.13 : Detection of Apoptosis by Annexin in NCM460  (after DE8 protein 
  application). 
 
Figure A.14 : Detection of Apoptosis by Annexin in NCM460  (after DE103 protein 
application). 
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APPENDIX B : Detection of Apoptosis by Annexin in CRL1790 
 
Figure B.1 :  Detection of Apoptosis by Annexin in CRL1790 (negative- cell 
     without antibody). 
 
Figure B.2 : Detection of Apoptosis by Annexin in CRL1790 (only annexin). 
 
 
Figure B.3 : Detection of Apoptosis by Annexin in CRL1790 (only pi). 
 
Figure B.4 : Detection of Apoptosis by Annexin in CRL1790 (cell before bacterial 
protein application). 
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Figure B.5 : Detection of Apoptosis by Annexin in CRL1790 (after 3h protein 
   application). 
 
Figure B.6 : Detection of Apoptosis by Annexin in CRL1790 (after huc2 protein 
 application). 
 
Figure B.7 : Detection of Apoptosis by Annexin in CRL1790 (after DE47 protein 
application). 
 
Figure B.8 : Detection of Apoptosis by Annexin in CRL1790 (after DE256 protein 
application). 
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Figure B.9 : Detection of Apoptosis by Annexin in CRL1790 (after DE129 protein 
application). 
 
Figure B.10 : Detection of Apoptosis by Annexin in CRL1790 (after DE36 protein 
application). 
 
Figure B.11 : Detection of Apoptosis by Annexin in CRL1790 (after DE51 protein 
application). 
 
Figure B.12 : Detection of Apoptosis by Annexin in CRL1790 (after DE12 protein 
application). 
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Figure B.13 : Detection of Apoptosis by Annexin in CRL1790 (after DE103 protein 
application). 
 
Figure B.14 : Detection of Apoptosis by Annexin in CRL1790 (after DB7Y protein 
application). 
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APPENDIX C: CD24 Detection in CRL1790 
 
Figure C.1: CD24 Detection in CRL1790 cell line - negative (cell without antibody). 
 
Figure C.2: CD24 Detection in CRL1790 cell line – (cell before bacterial protein 
application). 
 
Figure C.3: CD24 Detection in CRL1790 cell line – (isotype, before bacterial 
   protein application). 
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Figure C.4: CD24 Detection in CRL1790 cell line – (after 3h bacterial protein 
   application). 
 
Figure C.5: CD24 Detection in CRL1790 cell line – (isotype after 3h bacterial 
  protein application). 
 
Figure C.6: CD24 Detection in CRL1790 cell line – ( after huc2 bacterial protein  
                        application). 
 
Figure C.7: CD24 Detection in CRL1790 cell line – (isotype after huc bacterial 
 protein application) 
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Figure C.8: CD24 Detection in CRL1790 cell line – (after DE256 bacterial protein 
application). 
 
Figure C.9: CD24 Detection in CRL1790 cell line – (isotype after DE256 bacterial 
                      protein application). 
 
Figure C.10: CD24 Detection in CRL1790 cell line – (after DE36 bacterial protein 
application). 
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Figure C.11: CD24 Detection in CRL1790 cell line – (isotype after DE36 bacterial 
protein application). 
 
Figure C.12: CD24 Detection in CRL1790 cell line – (after DE51 bacterial protein 
application). 
 
Figure C.13: CD24 Detection in CRL1790 cell line – (isotype after DE51 bacterial 
protein application). 
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Figure C.14: CD24 Detection in CRL1790 cell line – (after DE103 bacterial protein 
application) 
 
Figure C.15: CD24 Detection in CRL1790 cell line – (isotype after DE103 bacterial 
protein application). 
 
Figure C.16: CD24 Detection in CRL1790 cell line – (after DE129 bacterial protein 
application). 
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Figure C.17: CD24 Detection in CRL1790 cell line – (isotype after DE129 bacterial 
protein application). 
 
Figure C.18: CD24 Detection in CRL1790 cell line – (after DE12 bacterial protein 
application). 
 
Figure C.19: CD24 Detection in CRL1790 cell line – (isotype after DE12 bacterial 
protein application). 
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Figure C.20: CD24 Detection in CRL1790 cell line – (after DE47 bacterial protein 
application) 
 
Figure C.21: CD24 Detection in CRL1790 cell line – ( isotype after DE47 bacterial 
protein application) 
 
Figure C.22: CD24 Detection in CRL1790 cell line – (after DB7Y bacterial 
       protein application). 
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Figure C.23: CD24 Detection in CRL1790 cell line – (isotype after DB7Y bacterial 
protein application). 
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APPENDIX D: CD24 Detection in NCM460 
 
Figure D.1: CD24 Detection in NCM 460 cell line (negative : cell without antibody). 
 
Figure D.2: CD24 Detection in NCM 460 cell line – (cell before bacterial protein 
application). 
 
Figure D.3: CD24 Detection in NCM 460 cell line (isotype, before bacterial protein 
          application). 
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Figure D.4: CD24 Detection in NCM 460 cell line (after 3h bacterial protein 
    application). 
 
Figure D.5: CD24 Detection in NCM 460 cell line (isotype after 3h bacterial protein 
         application). 
 
Figure D.6: CD24 Detection in NCM 460 cell line (after HIA bacterial protein 
  application). 
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Figure D.7: CD24 Detection in NCM 460 cell line (isotype after HIA bacterial 
  protein application). 
 
Figure D.8: CD24 Detection in NCM 460 cell line (after huc2 bacterial protein 
application). 
 
Figure D.9: CD24 Detection in NCM 460 cell line (isotype, after huc2 bacterial 
 protein application). 
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Figure D.10: CD24 Detection in NCM 460 cell line (after DE256 bacterial protein 
application). 
 
Figure D.11: CD24 Detection in NCM 460 cell line (isotype after DE256 bacterial 
protein application). 
 
Figure D.12: CD24 Detection in NCM 460 cell line (after DE36 bacterial protein 
  application). 
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Figure D.13: CD24 Detection in NCM 460 cell line (isotype, after DE36 bacterial 
 protein application). 
 
Figure D.14: CD24 Detection in NCM 460 cell line (after DE51 bacterial protein 
  application). 
 
Figure D.15: CD24 Detection in NCM 460 cell line (isotype, after DE51 bacterial 
 protein application). 
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Figure D.16: CD24 Detection in NCM 460 cell line (after DE365 bacterial protein 
 application). 
 
Figure D.17: CD24 Detection in NCM 460 cell line (isotype, after DE365 bacterial 
protein application). 
 
Figure D.18: CD24 Detection in NCM 460 cell line (after DE103 bacterial protein 
application). 
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Figure D.19: CD24 Detection in NCM 460 cell line (isotype, after DE103 bacterial 
protein application). 
 
Figure D.20: CD24 Detection in NCM 460 cell line (after DE129 bacterial protein 
application). 
 
Figure D.21: CD24 Detection in NCM 460 cell line (isotype, after DE129 bacterial 
protein application). 
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Figure D.22: CD24 Detection in NCM 460 cell line (after DE8 bacterial protein 
   application). 
 
Figure D.23: CD24 Detection in NCM 460 cell line (isotype, after DE8 bacterial 
  protein application). 
 
Figure D.24: CD24 Detection in NCM 460 cell line (after DE12 bacterial protein 
  application). 
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Figure D.25: CD24 Detection in NCM 460 cell line (isotype, after DE12 bacterial 
  protein application). 
 
Figure D.26: CD24 Detection in NCM 460 cell line (after DE47 bacterial protein 
  application). 
 
Figure D.27: CD24 Detection in NCM 460 cell line (isotype, after DE47 bacterial 
  protein application). 
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Figure D.28: CD24 Detection in NCM 460 cell line (after DB7Y bacterial protein 
 application). 
 
Figure D.29: CD24 Detection in NCM 460 cell line (isotype, after DB7Y bacterial 
 protein application). 
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APPENDIX E : MIS Results 
E.1: MIS Result of 3h  
 
Volume: DATA            File: E131045.99A        Samp Ctr: 12                ID Number: 8489  
Type: Samp                   Bottle: 11                      Method: RCLIN6  
Created: 1/4/2013 3:55:36 PM  
Sample ID: 3h  
 
RT Response Ar/Ht RFact ECL Peak Name Percent Comment1 Comment2 
0.6919 273101 0.004 ---- 6.6791  ---- < min rt  
0.7003 9.835E+8 0.016 ---- 6.7415 SOLVENT 
PEAK 
---- < min rt  
1.5261 2257 0.008 1.045 11.9998 12:0 2.09 ECL deviates  
0.000 
Reference -0.004 
1.7772 1161 0.009 0.998 13.0009 13:0 1.02 ECL deviates  
0.001 
Reference -0.003 
2.0571 7430 0.009 0.965 13.9991 14:0 6.34 ECL deviates -
0.001 
Reference -0.005 
2.2084 2468 0.010 0.953 14.5050 Sum In Feature 1 2.08 ECL deviates  
0.002 
13:0 3OH/15:1 iso 
H 2.3007 367 0.008 0.947 14.8137 15:1 w8c 0.31 ECL deviates  
0.000 
 
2.3569 9478 0.009 0.944 15.0016 15:0 ---- ECL deviates  
0.002 
 
2.4122 462 0.009 ---- 15.1791  ----   
2.4292 1049 0.008 0.940 15.2336 14:0 2OH 0.87 ECL deviates  
0.000 
 
2.5174 10052 0.008 0.937 15.5166 Sum In Feature 2 8.32 ECL deviates  
0.001 
14:0 3OH/16:1 iso 
I 2.6167 7044 0.009 0.933 15.8354 Sum In Feature 3 5.81 ECL deviates -
0.005 
16:1 w7c/16:1 w6c 
2.6463 326 0.009 0.932 15.9303 16:1 w5c 0.27 ECL deviates  
0.002 
 
2.6677 31805 0.009 0.931 15.9990 16:0 26.19 ECL deviates -
0.001 
Reference -0.007 
2.6974 1164 0.012 ---- 16.0941  ----   
2.8340 618 0.010 0.927 16.5307 15:0 3OH 0.51 ECL deviates -
0.002 
 
2.9236 476 0.009 0.926 16.8171 17:1 w8c 0.39 ECL deviates  
0.002 
 
2.9539 23125 0.009 0.925 16.9139 17:0 cyclo 18.91 ECL deviates -
0.001 
 
2.9815 8389 0.009 0.925 17.0022 17:0 6.86 ECL deviates  
0.002 
Reference -0.004 
3.2172 1073 0.010 0.922 17.7545 Sum In Feature 5 0.87 ECL deviates -
0.001 
18:2 w6,9c/18:0 
ante 3.2447 15736 0.009 0.922 17.8423 Sum In Feature 8 12.82 ECL deviates -
0.005 
18:1 w7c 
3.2626 1120 0.012 0.922 17.8996 Sum In Feature 8 0.91 ECL deviates -
0.002 
18:1 w6c 
3.2938 1233 0.010 0.921 17.9990 18:0 1.00 ECL deviates -
0.001 
Reference -0.008 
3.4381 1487 0.012 ---- 18.4698  ----   
3.5050 791 0.010 ---- 18.6883  ----   
3.5779 4221 0.010 0.918 18.9262 19:0 cyclo w8c 3.42 ECL deviates -
0.006 
 
3.5981 654 0.010 0.917 18.9922 19:0 0.53 ECL deviates -
0.008 
 
3.6456 581 0.010 0.917 19.1502 18:1 2OH 0.47 ECL deviates  
0.004 
 
---- 2468 --- ---- ---- Summed Feature 
1 
2.08 15:1 iso H/13:0 
3OH 
13:0 3OH/15:1 iso 
H ---- 10052 --- ---- ---- Summed Feature 
2 
8.32 12:0 aldehyde ? unknown 10.9525 
---- ----- --- ---- ----  ---- 16:1 iso I/14:0 
3OH 
14:0 3OH/16:1 iso 
I ---- 7044 --- ---- ---- Summed Feature 
3 
5.81 16:1 w7c/16:1 w6c 16:1 w6c/16:1 w7c 
---- 1073 --- ---- ---- Summed Feature 
5 
0.87 18:0 ante/18:2 
w6,9c 
18:2 w6,9c/18:0 
ante ---- 16856 --- ---- ---- Summed Feature 
8 
13.73 18:1 w7c 18:1 w6c 
 
ECL Deviation: 0.003                            Reference ECL Shift: 0.005      Number Reference Peaks: 6 
Total Response: 125090                         Total Named: 121185 
Percent Named: 96.88%                         Total Amount: 122068 
 
Matches:  
 
Library Sim Index Entry Name 
RCLIN6 6.00 0.507 Enterobacter-cloacae-GC subgroup B  
 0.487 Kluyvera-cryocrescens  
 0.481 Klebsiella-pneumoniae-pneumoniae-GC subgroup C  
 0.478 Escherichia-coli-GC subgroup A (high DNA homol. with Shigella) 
 0.381 Escherichia-coli-O157:H7-GC subgroup A  
 0.347 Enterobacter-aerogenes-GC subgroup B  
 0.347 Enterobacter-aerogenes-GC subgroup A  
 0.340 Shigella-boydii-GC subgroup A  (high DNA homol. with E. coli) 
 0.336 Escherichia-coli-GC subgroup B1 (high DNA homol. with Shigella) 
 0.325 Salmonella-typhimurium  
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E.2: MIS Result of huc2  
Volume: DATA            File: E118255.87A        Samp Ctr: 13                ID Number: 7407  
Type: Samp                   Bottle: 12                      Method: RTSBA6         Calc. Method: RCLIN6  
Created: 8/25/2011 3:47:01 PM  
Sample ID: huc2  
 
RT Response Ar/Ht RFact ECL Peak Name Percent Comment1 Comment2 
0.6916 428489 0.004 ---- 6.6653  ---- < min rt  
0.7007 1.226E+9 0.015 ---- 6.7332 SOLVENT 
PEAK 
---- < min rt  
1.1684 1878 0.009 ---- 10.1505  ----   
1.3069 926 0.013 1.069 10.9491 Sum In Feature 2 0.32 ECL deviates -
0.003 
unknown 10.9525 
1.5320 10022 0.008 1.022 12.0009 12:0 3.34 ECL deviates  
0.001 
Reference -0.001 
1.7839 3539 0.008 0.989 13.0004 13:0 1.14 ECL deviates  
0.000 
Reference -0.001 
1.9257 521 0.011 ---- 13.5045  ----   
2.0179 573 0.010 ---- 13.8322  ----   
2.0644 23034 0.009 0.967 13.9975 14:0 7.27 ECL deviates -
0.002 
Reference -0.003 
2.2162 4952 0.011 0.959 14.5037 Sum In Feature 1 1.55 ECL deviates  
0.001 
13:0 3OH/15:1 iso 
H 2.3089 714 0.009 0.955 14.8127 15:1 w8c 0.22 ECL deviates -
0.001 
 
2.3648 22213 0.008 0.953 14.9990 15:0 ---- ECL deviates -
0.001 
 
2.4202 794 0.009 ---- 15.1772  ----   
2.5257 24900 0.008 0.948 15.5164 Sum In Feature 2 7.71 ECL deviates  
0.001 
14:0 3OH/16:1 iso 
I 2.6248 33165 0.009 0.946 15.8348 Sum In Feature 3 10.25 ECL deviates -
0.005 
16:1 w7c/16:1 w6c 
2.6541 743 0.010 0.946 15.9291 16:1 w5c 0.23 ECL deviates  
0.001 
 
2.6760 96098 0.008 0.946 15.9997 16:0 29.67 ECL deviates  
0.000 
Reference -0.003 
2.7066 1249 0.012 ---- 16.0975  ----   
2.8423 840 0.011 0.944 16.5309 15:0 3OH 0.26 ECL deviates -
0.002 
 
2.9310 1321 0.010 0.944 16.8142 17:1 w8c 0.41 ECL deviates -
0.001 
 
2.9623 52040 0.009 0.944 16.9141 17:0 cyclo 16.03 ECL deviates -
0.001 
 
2.9896 13355 0.009 0.944 17.0014 17:0 4.11 ECL deviates  
0.001 
Reference -0.003 
3.2249 1009 0.010 0.945 17.7559 Sum In Feature 5 0.31 ECL deviates  
0.000 
18:2 w6,9c/18:0 
ante 3.2531 41729 0.010 0.945 17.8462 Sum In Feature 8 12.87 ECL deviates -
0.001 
18:1 w7c 
3.2712 1920 0.009 0.945 17.9044 Sum In Feature 8 0.59 ECL deviates  
0.002 
18:1 w6c 
3.2863 631 0.008 ---- 17.9528  ----   
3.3017 1263 0.010 0.945 18.0019 18:0 0.39 ECL deviates  
0.002 
Reference -0.005 
3.4471 1066 0.012 ---- 18.4782  ----   
3.5131 751 0.010 ---- 18.6944  ----   
3.5863 10319 0.009 0.948 18.9340 19:0 cyclo w8c 3.19 ECL deviates  
0.002 
 
3.6058 389 0.010 0.948 18.9981 19:0 0.12 ECL deviates -
0.002 
Reference -0.012 
---- 4952 --- ---- ---- Summed Feature 
1 
1.55 15:1 iso H/13:0 
3OH 
13:0 3OH/15:1 iso 
H ---- 25826 --- ---- ---- Summed Feature 
2 
8.03 12:0 aldehyde ? unknown 10.9525 
---- ----- --- ---- ----  ---- 16:1 iso I/14:0 
3OH 
14:0 3OH/16:1 iso 
I ---- 33165 --- ---- ---- Summed Feature 
3 
10.25 16:1 w7c/16:1 w6c 16:1 w6c/16:1 w7c 
---- 1009 --- ---- ---- Summed Feature 
5 
0.31 18:0 ante/18:2 
w6,9c 
18:2 w6,9c/18:0 
ante ---- 43649 --- ---- ---- Summed Feature 
8 
13.46 18:1 w7c 18:1 w6c 
 
ECL Deviation: 0.002                            Reference ECL Shift: 0.005      Number Reference Peaks: 7 
Total Response: 329739                         Total Named: 322277 
Percent Named: 97.74%                         Total Amount: 327468 
 
Matches:  
 
Library Sim Index Entry Name 
RCLIN6 6.00 0.821 Enterobacter-cloacae-GC subgroup B  
 0.746 Escherichia-coli-GC subgroup A (high DNA homol. with Shigella) 
 0.733 Klebsiella-oxytoca  
 0.716 Kluyvera-cryocrescens  
 0.680 Enterobacter-cancerogenus  
 0.662 Enterobacter-aerogenes-GC subgroup B  
 0.615 Klebsiella-pneumoniae-pneumoniae-GC subgroup C  
 0.603 Shigella-sonnei-GC subgroup B (high DNA homol. with E. coli) 
 0.593 Kluyvera-ascorbata  
 0.561 Enterobacter-asburiae  
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E.3: MIS Result of DE8  
Volume: DATA            File: E131045.99A        Samp Ctr: 5                  ID Number: 8482  
Type: Samp                   Bottle: 4                        Method: RCLIN6  
Created: 1/4/2013 2:55:44 PM  
Sample ID: DE 8  
 
RT Response Ar/Ht RFact ECL Peak Name Percent Comment1 Comment2 
0.6916 307960 0.004 ---- 6.6769  ---- < min rt  
0.6998 9.868E+8 0.016 ---- 6.7383 SOLVENT 
PEAK 
---- < min rt  
1.3013 365 0.008 1.114 10.9415 Sum In Feature 2 0.22 ECL deviates -
0.011 
unknown 10.9525 
1.5260 1456 0.008 1.045 12.0000 12:0 0.81 ECL deviates  
0.000 
Reference -0.004 
1.7770 807 0.010 0.998 13.0005 13:0 0.43 ECL deviates  
0.000 
Reference -0.004 
1.9286 383 0.008 ---- 13.5414  ----   
2.0570 21007 0.008 0.965 13.9993 14:0 10.82 ECL deviates -
0.001 
Reference -0.006 
2.2087 2551 0.012 0.953 14.5065 Sum In Feature 1 1.30 ECL deviates  
0.004 
13:0 3OH/15:1 iso 
H 2.3568 8894 0.008 0.944 15.0019 15:0 ---- ECL deviates  
0.002 
 
2.4125 556 0.009 ---- 15.1806  ----   
2.4289 1826 0.009 0.940 15.2333 14:0 2OH 0.92 ECL deviates  
0.000 
 
2.5173 15986 0.009 0.937 15.5170 Sum In Feature 2 7.99 ECL deviates  
0.002 
14:0 3OH/16:1 iso 
I 2.6167 15395 0.009 0.933 15.8360 Sum In Feature 3 7.67 ECL deviates -
0.004 
16:1 w7c/16:1 w6c 
2.6443 338 0.009 0.932 15.9245 16:1 w5c 0.17 ECL deviates -
0.004 
 
2.6676 62092 0.009 0.931 15.9993 16:0 30.87 ECL deviates -
0.001 
Reference -0.007 
2.6971 625 0.010 ---- 16.0938  ----   
2.7463 318 0.010 0.929 16.2508 15:0 2OH 0.16 ECL deviates -
0.004 
 
2.8340 406 0.009 0.927 16.5312 15:0 3OH 0.20 ECL deviates -
0.002 
 
2.9227 537 0.010 0.926 16.8149 17:1 w8c 0.27 ECL deviates  
0.000 
 
2.9533 31448 0.009 0.925 16.9125 17:0 cyclo 15.53 ECL deviates -
0.003 
 
2.9812 7247 0.009 0.925 17.0018 17:0 3.58 ECL deviates  
0.002 
Reference -0.005 
3.2169 538 0.010 0.922 17.7542 Sum In Feature 5 0.26 ECL deviates -
0.002 
18:2 w6,9c/18:0 
ante 3.2446 23292 0.009 0.922 17.8427 Sum In Feature 8 11.46 ECL deviates -
0.005 
18:1 w7c 
3.2626 1376 0.009 0.922 17.9001 Sum In Feature 8 0.68 ECL deviates -
0.002 
18:1 w6c 
3.2772 361 0.007 0.921 17.9466 18:1 w5c 0.18 ECL deviates  
0.010 
 
3.2936 1866 0.009 0.921 17.9991 18:0 0.92 ECL deviates -
0.001 
Reference -0.009 
3.4380 701 0.009 ---- 18.4703  ----   
3.5049 546 0.011 ---- 18.6887  ----   
3.5778 10577 0.010 0.918 18.9266 19:0 cyclo w8c 5.18 ECL deviates -
0.005 
 
3.5970 383 0.011 0.917 18.9893 19:0 0.19 ECL deviates -
0.011 
 
3.6451 447 0.011 0.917 19.1491 18:1 2OH 0.22 ECL deviates  
0.003 
 
4.2573 384 0.010 ---- 21.1896  ---- > max rt  
---- 2551 --- ---- ---- Summed Feature 
1 
1.30 15:1 iso H/13:0 
3OH 
13:0 3OH/15:1 iso 
H ---- 16351 --- ---- ---- Summed Feature 
2 
8.21 12:0 aldehyde ? unknown 10.9525 
---- ----- --- ---- ----  ---- 16:1 iso I/14:0 
3OH 
14:0 3OH/16:1 iso 
I ---- 15395 --- ---- ---- Summed Feature 
3 
7.67 16:1 w7c/16:1 w6c 16:1 w6c/16:1 w7c 
---- 538 --- ---- ---- Summed Feature 
5 
0.26 18:0 ante/18:2 
w6,9c 
18:2 w6,9c/18:0 
ante ---- 24668 --- ---- ---- Summed Feature 
8 
12.14 18:1 w7c 18:1 w6c 
 
ECL Deviation: 0.004                            Reference ECL Shift: 0.006      Number Reference Peaks: 6 
Total Response: 203430                         Total Named: 200619 
Percent Named: 98.62%                         Total Amount: 195750 
 
Matches:  
 
Library Sim Index Entry Name 
RCLIN6 6.00 0.826 Enterobacter-aerogenes-GC subgroup A  
 0.806 Enterobacter-cloacae-GC subgroup C  
 0.795 Klebsiella-pneumoniae-pneumoniae-GC subgroup C  
 0.791 Enterobacter-aerogenes-GC subgroup B  
 0.704 Enterobacter-cloacae-GC subgroup B  
 0.676 Proteus-mirabilis-GC subgroup A  
 0.625 Escherichia-coli-GC subgroup A (high DNA homol. with Shigella) 
 0.579 Klebsiella-pneumoniae-pneumoniae-GC subgroup A  
 0.577 Mannheimia-haemolytica-GC subgroup B  (Pasteurella) 
 0.575 Klebsiella-oxytoca  
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E.4: MIS Result of DB7Y  
Volume: DATA            File: E131084.18A        Samp Ctr: 4                  ID Number: 8497  
Type: Samp                   Bottle: 3                        Method: RCLIN6         Calc. Method: RTSBA6  
Created: 1/8/2013 10:26:54 AM  
Sample ID: DB7Y  
 
RT Response Ar/Ht RFact ECL Peak Name Percent Comment1 Comment2 
0.6917 276247 0.004 ---- 6.6820  ---- < min rt  
0.7000 9.751E+8 0.016 ---- 6.7436 SOLVENT 
PEAK 
---- < min rt  
1.3021 321 0.008 1.104 10.9449 Sum In Feature 2 0.24 ECL deviates -
0.008 
unknown 10.9525 
1.5261 5888 0.008 1.039 11.9995 12:0 4.09 ECL deviates  
0.000 
Reference -0.004 
1.7772 2781 0.009 0.994 13.0013 13:0 1.85 ECL deviates  
0.001 
Reference -0.003 
1.9190 469 0.012 ---- 13.5064  ----   
2.0459 1015 0.007 0.965 13.9585 unknown 13.951 ---- ECL deviates  
0.008 
 
2.0573 9455 0.008 0.964 13.9991 14:0 6.10 ECL deviates -
0.001 
Reference -0.006 
2.2078 3978 0.010 0.953 14.5020 Sum In Feature 1 2.54 ECL deviates -
0.001 
13:0 3OH/15:1 iso 
H 2.3007 560 0.009 0.948 14.8122 15:1 w8c 0.36 ECL deviates -
0.002 
 
2.3570 17333 0.009 0.945 15.0003 15:0 ---- ECL deviates  
0.000 
 
2.4121 711 0.010 ---- 15.1774  ----   
2.5179 15177 0.009 0.939 15.5172 Sum In Feature 2 9.53 ECL deviates  
0.002 
14:0 3OH/16:1 iso 
I 2.6174 18865 0.009 0.936 15.8367 Sum In Feature 3 11.81 ECL deviates -
0.003 
16:1 w7c/16:1 w6c 
2.6460 473 0.009 0.935 15.9288 16:1 w5c 0.30 ECL deviates  
0.001 
 
2.6680 38356 0.008 0.934 15.9994 16:0 23.98 ECL deviates -
0.001 
Reference -0.006 
2.6988 807 0.011 ---- 16.0976  ----   
2.8347 837 0.010 0.931 16.5312 15:0 3OH 0.52 ECL deviates -
0.002 
 
2.9233 584 0.010 0.930 16.8139 17:1 w8c 0.36 ECL deviates -
0.001 
 
2.9542 26348 0.009 0.930 16.9125 17:0 cyclo 16.39 ECL deviates -
0.002 
 
2.9819 7704 0.009 0.930 17.0010 17:0 4.79 ECL deviates  
0.001 
Reference -0.005 
3.2174 787 0.010 0.928 17.7541 Sum In Feature 5 0.49 ECL deviates -
0.002 
18:2 w6,9c/18:0 
ante 3.2453 21193 0.009 0.928 17.8432 Sum In Feature 8 13.16 ECL deviates -
0.004 
18:1 w7c 
3.2635 1118 0.010 0.928 17.9015 Sum In Feature 8 0.69 ECL deviates -
0.001 
18:1 w6c 
3.2942 965 0.009 0.927 17.9996 18:0 0.60 ECL deviates  
0.000 
Reference -0.007 
3.4389 1090 0.012 ---- 18.4724  ----   
3.5053 611 0.011 ---- 18.6893  ----   
3.5788 2365 0.009 0.925 18.9297 19:0 cyclo w8c 1.46 ECL deviates -
0.002 
 
3.5977 464 0.009 0.925 18.9914 19:0 0.29 ECL deviates -
0.009 
 
3.6452 742 0.011 0.924 19.1486 18:1 2OH 0.46 ECL deviates  
0.003 
 
---- 3978 --- ---- ---- Summed Feature 
1 
2.54 15:1 iso H/13:0 
3OH 
13:0 3OH/15:1 iso 
H ---- 15498 --- ---- ---- Summed Feature 
2 
9.77 12:0 aldehyde ? unknown 10.9525 
---- ----- --- ---- ----  ---- 16:1 iso I/14:0 
3OH 
14:0 3OH/16:1 iso 
I ---- 18865 --- ---- ---- Summed Feature 
3 
11.81 16:1 w7c/16:1 w6c 16:1 w6c/16:1 w7c 
---- 787 --- ---- ---- Summed Feature 
5 
0.49 18:0 ante/18:2 
w6,9c 
18:2 w6,9c/18:0 
ante ---- 22311 --- ---- ---- Summed Feature 
8 
13.85 18:1 w7c 18:1 w6c 
 
ECL Deviation: 0.003                            Reference ECL Shift: 0.005      Number Reference Peaks: 6 
Total Response: 162647                         Total Named: 158960 
Percent Named: 97.73%                         Total Amount: 166817 
 
Matches:  
 
Library Sim Index Entry Name 
RTSBA6 6.00 0.380 Enterobacter-cancerogenus (Erwinia cancerogena) 
 0.349 Enterobacter-hormaechei  
 0.286 Escherichia-fergusonii-GC subgroup A  
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E.5: MIS Result of DE12  
Volume: DATA            File: E131045.99A        Samp Ctr: 17                ID Number: 8493  
Type: Samp                   Bottle: 15                      Method: RCLIN6  
Created: 1/4/2013 4:38:07 PM  
Sample ID: DE 12  
 
RT Response Ar/Ht RFact ECL Peak Name Percent Comment1 Comment2 
0.6919 278168 0.004 ---- 6.6745  ---- < min rt  
0.7002 9.762E+8 0.016 ---- 6.7362 SOLVENT 
PEAK 
---- < min rt  
1.3021 491 0.012 1.105 10.9478 Sum In Feature 2 0.35 ECL deviates -
0.005 
unknown 10.9525 
1.5265 5798 0.008 1.039 12.0007 12:0 3.89 ECL deviates  
0.001 
Reference -0.001 
1.7777 794 0.012 0.994 13.0008 13:0 0.51 ECL deviates  
0.001 
Reference  0.000 
1.9293 532 0.013 ---- 13.5403  ----   
2.0576 10489 0.009 0.964 13.9973 14:0 6.53 ECL deviates -
0.003 
Reference -0.002 
2.2113 1890 0.011 0.953 14.5108 unknown 14.502 ---- ECL deviates -
0.005 
 
2.3576 4333 0.008 0.945 14.9993 15:0 ---- ECL deviates -
0.001 
 
2.4126 650 0.009 ---- 15.1761  ----   
2.5180 14563 0.009 0.938 15.5154 Sum In Feature 2 8.82 ECL deviates  
0.000 
14:0 3OH/16:1 iso 
I 2.6175 18086 0.009 0.935 15.8356 Sum In Feature 3 10.92 ECL deviates -
0.004 
16:1 w7c/16:1 w6c 
2.6685 52994 0.009 0.934 15.9998 16:0 31.95 ECL deviates  
0.000 
Reference  0.000 
2.6979 1380 0.012 ---- 16.0937  ----   
2.9321 340 0.007 0.930 16.8426 17:1 w7c 0.20 ECL deviates  
0.007 
 
2.9546 29492 0.009 0.929 16.9145 17:0 cyclo 17.69 ECL deviates -
0.001 
 
2.9817 3271 0.009 0.929 17.0012 17:0 1.96 ECL deviates  
0.001 
Reference  0.000 
3.2173 1149 0.009 0.927 17.7551 Sum In Feature 5 0.69 ECL deviates -
0.001 
18:2 w6,9c/18:0 
ante 3.2452 23082 0.010 0.927 17.8447 Sum In Feature 8 13.81 ECL deviates -
0.003 
18:1 w7c 
3.2944 1480 0.009 0.927 18.0021 18:0 0.89 ECL deviates  
0.002 
Reference -0.002 
3.4382 1643 0.012 ---- 18.4735  ----   
3.5057 899 0.011 ---- 18.6949  ----   
3.5785 1873 0.010 0.924 18.9338 19:0 cyclo w8c 1.12 ECL deviates  
0.002 
 
3.5981 587 0.009 0.924 18.9981 19:0 0.35 ECL deviates -
0.002 
Reference -0.009 
3.6463 535 0.012 0.924 19.1587 18:1 2OH 0.32 ECL deviates  
0.013 
 
---- 15054 --- ---- ---- Summed Feature 
2 
9.17 12:0 aldehyde ? unknown 10.9525 
---- ----- --- ---- ----  ---- 16:1 iso I/14:0 
3OH 
14:0 3OH/16:1 iso 
I ---- 18086 --- ---- ---- Summed Feature 
3 
10.92 16:1 w7c/16:1 w6c 16:1 w6c/16:1 w7c 
---- 1149 --- ---- ---- Summed Feature 
5 
0.69 18:0 ante/18:2 
w6,9c 
18:2 w6,9c/18:0 
ante ---- 23082 --- ---- ---- Summed Feature 
8 
13.81 18:1 w7c 18:1 w6c 
 
ECL Deviation: 0.004                            Reference ECL Shift: 0.003      Number Reference Peaks: 7 
Total Response: 170128                         Total Named: 165025 
Percent Named: 97.00%                         Total Amount: 160817 
 
Matches:  
 
Library Sim Index Entry Name 
RCLIN6 6.00 0.833 Enterobacter-cancerogenus  
 0.833 Enterobacter-cloacae-GC subgroup B  
 0.824 Klebsiella-pneumoniae-rhinoscleromatis-GC subgroup B  
 0.820 Klebsiella-oxytoca  
 0.783 Enterobacter-cloacae-GC subgroup D  
 0.758 Kluyvera-ascorbata  
 0.649 Enterobacter-asburiae  
 0.636 Shigella-boydii-GC subgroup A  (high DNA homol. with E. coli) 
 0.609 Escherichia-coli-GC subgroup A (high DNA homol. with Shigella) 
 0.582 Kluyvera-cryocrescens  
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E.6: MIS Result of DE256 
Volume: DATA            File: E131045.99A        Samp Ctr: 16                ID Number: 8492  
Type: Samp                   Bottle: 14                      Method: RCLIN6  
Created: 1/4/2013 4:29:40 PM  
Sample ID: DE 256  
 
RT Response Ar/Ht RFact ECL Peak Name Percent Comment1 Comment2 
0.6919 291290 0.004 ---- 6.6770  ---- < min rt  
0.7003 9.711E+8 0.016 ---- 6.7394 SOLVENT 
PEAK 
---- < min rt  
1.5260 3422 0.008 1.039 12.0003 12:0 2.45 ECL deviates  
0.000 
Reference -0.003 
1.7774 1146 0.010 0.994 13.0012 13:0 0.79 ECL deviates  
0.001 
Reference -0.001 
2.0572 11489 0.009 0.964 13.9976 14:0 7.64 ECL deviates -
0.002 
Reference -0.004 
2.2091 2294 0.011 0.953 14.5051 Sum In Feature 1 1.51 ECL deviates  
0.002 
13:0 3OH/15:1 iso 
H 2.3570 8641 0.009 0.945 14.9987 15:0 ---- ECL deviates -
0.001 
 
2.4119 592 0.009 ---- 15.1755  ----   
2.5174 13169 0.009 0.938 15.5151 Sum In Feature 2 8.53 ECL deviates  
0.000 
14:0 3OH/16:1 iso 
I 2.6170 11464 0.009 0.935 15.8355 Sum In Feature 3 7.40 ECL deviates -
0.004 
16:1 w7c/16:1 w6c 
2.6679 45790 0.009 0.934 15.9992 16:0 29.51 ECL deviates -
0.001 
Reference -0.002 
2.6976 1260 0.012 ---- 16.0944  ----   
2.8331 409 0.010 ---- 16.5275  ----   
2.9312 617 0.014 0.930 16.8412 17:1 w7c 0.40 ECL deviates  
0.005 
 
2.9538 29163 0.009 0.929 16.9135 17:0 cyclo 18.70 ECL deviates -
0.002 
 
2.9816 6243 0.009 0.929 17.0022 17:0 4.00 ECL deviates  
0.002 
Reference -0.001 
3.2170 1069 0.010 0.927 17.7555 Sum In Feature 5 0.68 ECL deviates -
0.001 
18:2 w6,9c/18:0 
ante 3.2446 20668 0.009 0.927 17.8438 Sum In Feature 8 13.22 ECL deviates -
0.004 
18:1 w7c 
3.2633 710 0.010 0.927 17.9038 Sum In Feature 8 0.45 ECL deviates  
0.002 
18:1 w6c 
3.2937 1687 0.010 0.927 18.0008 18:0 1.08 ECL deviates  
0.001 
Reference -0.004 
3.4378 1433 0.011 ---- 18.4734  ----   
3.5051 762 0.010 ---- 18.6940  ----   
3.5777 5174 0.009 0.924 18.9322 19:0 cyclo w8c 3.30 ECL deviates  
0.000 
 
3.5980 561 0.008 0.924 18.9987 19:0 0.36 ECL deviates -
0.001 
Reference -0.009 
3.6462 589 0.010 ---- 19.1592  ----   
---- 2294 --- ---- ---- Summed Feature 
1 
1.51 15:1 iso H/13:0 
3OH 
13:0 3OH/15:1 iso 
H ---- 13169 --- ---- ---- Summed Feature 
2 
8.53 12:0 aldehyde ? unknown 10.9525 
---- ----- --- ---- ----  ---- 16:1 iso I/14:0 
3OH 
14:0 3OH/16:1 iso 
I ---- 11464 --- ---- ---- Summed Feature 
3 
7.40 16:1 w7c/16:1 w6c 16:1 w6c/16:1 w7c 
---- 1069 --- ---- ---- Summed Feature 
5 
0.68 18:0 ante/18:2 
w6,9c 
18:2 w6,9c/18:0 
ante ---- 21377 --- ---- ---- Summed Feature 
8 
13.67 18:1 w7c 18:1 w6c 
 
ECL Deviation: 0.002                            Reference ECL Shift: 0.004      Number Reference Peaks: 7 
Total Response: 159710                         Total Named: 154665 
Percent Named: 96.84%                         Total Amount: 153125 
 
Matches:  
 
Library Sim Index Entry Name 
RCLIN6 6.00 0.781 Enterobacter-cloacae-GC subgroup B  
 0.759 Escherichia-coli-GC subgroup A (high DNA homol. with Shigella) 
 0.680 Shigella-boydii-GC subgroup A  (high DNA homol. with E. coli) 
 0.637 Klebsiella-oxytoca  
 0.598 Enterobacter-cloacae-GC subgroup C  
 0.573 Klebsiella-pneumoniae-pneumoniae-GC subgroup C  
 0.573 Enterobacter-aerogenes-GC subgroup A  
 0.569 Salmonella-typhimurium  
 0.568 Kluyvera-cryocrescens  
 0.558 Enterobacter-cancerogenus  
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E.7: MIS Result of DE103  
Volume: DATA            File: E131045.99A        Samp Ctr: 15                ID Number: 8491  
Type: Samp                   Bottle: 13                      Method: RCLIN6  
Created: 1/4/2013 4:21:05 PM  
Sample ID: DE 103  
 
RT Response Ar/Ht RFact ECL Peak Name Percent Comment1 Comment2 
0.6918 259891 0.004 ---- 6.6764  ---- < min rt  
0.7002 9.734E+8 0.016 ---- 6.7391 SOLVENT 
PEAK 
---- < min rt  
1.3021 638 0.013 1.105 10.9492 Sum In Feature 2 0.42 ECL deviates -
0.003 
unknown 10.9525 
1.5261 1837 0.009 1.039 12.0001 12:0 1.12 ECL deviates  
0.000 
Reference -0.003 
1.7776 919 0.013 0.994 13.0015 13:0 0.54 ECL deviates  
0.002 
Reference  0.000 
2.0574 16890 0.009 0.964 13.9976 14:0 9.58 ECL deviates -
0.002 
Reference -0.003 
2.2107 2430 0.011 ---- 14.5095  ----   
2.3572 6672 0.009 0.945 14.9984 15:0 ---- ECL deviates -
0.002 
 
2.4123 731 0.009 ---- 15.1759  ----   
2.5173 15292 0.009 0.938 15.5137 Sum In Feature 2 8.45 ECL deviates -
0.002 
14:0 3OH/16:1 iso 
I 2.6171 16455 0.008 0.935 15.8349 Sum In Feature 3 9.06 ECL deviates -
0.005 
16:1 w7c/16:1 w6c 
2.6681 55475 0.009 0.934 15.9990 16:0 30.51 ECL deviates -
0.001 
Reference -0.002 
2.6980 1177 0.012 ---- 16.0945  ----   
2.9250 335 0.009 0.930 16.8199 17:1 w8c 0.18 ECL deviates  
0.005 
 
2.9540 28135 0.009 0.929 16.9127 17:0 cyclo 15.39 ECL deviates -
0.002 
 
2.9822 6048 0.009 0.929 17.0028 17:0 3.31 ECL deviates  
0.003 
Reference  0.001 
3.2174 1058 0.010 0.927 17.7555 Sum In Feature 5 0.58 ECL deviates -
0.001 
18:2 w6,9c/18:0 
ante 3.2449 27570 0.010 0.927 17.8436 Sum In Feature 8 15.05 ECL deviates -
0.004 
18:1 w7c 
3.2634 661 0.011 0.927 17.9027 Sum In Feature 8 0.36 ECL deviates  
0.001 
18:1 w6c 
3.2938 1785 0.009 0.927 17.9999 18:0 0.97 ECL deviates  
0.000 
Reference -0.004 
3.4387 1410 0.012 ---- 18.4747  ----   
3.5050 754 0.010 ---- 18.6922  ----   
3.5783 7141 0.009 0.924 18.9327 19:0 cyclo w8c 3.89 ECL deviates  
0.001 
 
3.5986 552 0.009 0.924 18.9992 19:0 0.30 ECL deviates -
0.001 
Reference -0.007 
3.6451 529 0.010 0.924 19.1540 18:1 2OH 0.29 ECL deviates  
0.008 
 
---- 15929 --- ---- ---- Summed Feature 
2 
8.86 12:  aldehyde ? unknown 10.9525 
---- ----- --- ---- ----  ---- 16:1 iso I/14:0 
3OH 
14:0 3OH/16:1 iso 
I ---- 16455 --- ---- ---- Summed Feature 
3 
9.06 16:1 w7c/16:1 w6c 16:1 w6c/16:1 w7c 
---- 1058 --- ---- ---- Summed Feature 
5 
0.58 18:0 ante/18:2 
w6,9c 
18:2 w6,9c/18:0 
ante ---- 28231 --- ---- ---- Summed Feature 
8 
15.41 18:1 w7c 18:1 w6c 
 
ECL Deviation: 0.003                            Reference ECL Shift: 0.003      Number Reference Peaks: 7 
Total Response: 187821                         Total Named: 181319 
Percent Named: 96.54%                         Total Amount: 176158 
 
Matches:  
 
Library Sim Index Entry Name 
RCLIN6 6.00 0.897 Enterobacter-cloacae-GC subgroup B  
 0.788 Escherichia-coli-GC subgroup A (high DNA homol. with Shigella) 
 0.779 Enterobacter-aerogenes-GC subgroup B  
 0.723 Klebsiella-pneumoniae-pneumoniae-GC subgroup C  
 0.668 Shigella-boydii-GC subgroup A  (high DNA homol. with E. coli) 
 0.659 Proteus-mirabilis-GC subgroup A  
 0.656 Enterobacter-cloacae-GC subgroup C  
 0.635 Klebsiella-pneumoniae-pneumoniae-GC subgroup B  
 0.619 Kluyvera-ascorbata  
 0.604 Klebsiella-pneumoniae-ozaenae-type 6  
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APPENDIX  F : Microbial Identification VITEK2 Results 
 
Figure F.1: VITEK2 Result of DE36. 
 
Figure F.2: VITEK2 Result of DE129. 
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Figure F.3: VITEK2 Result of DE47. 
 
Figure F.4: VITEK2 Result of DE51. 
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Figure F.5: VITEK2 Result of DE365. 
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